POINT 6a
-
1
In patients undergoing thrombolytic therapy in the hyperacute phase of cerebral infarction, blood pressure should be controlled at <180/105 mm Hg within 24 h after treatment (Recommendation grade: C1, Evidence level: VI).
-
2
In the hyperacute (within 24 h after onset) and acute (within 2 weeks after onset) phases of cerebral infarction, for which thrombolytic therapy is not indicated, the target of blood pressure control should be 85–90% of the pretreatment value when systolic and diastolic blood pressures exceed 220 and 120 mm Hg, respectively (Recommendation grade: C1, Evidence level: III).
-
3
In the chronic phase of cerebral infarction (1 month or more after onset), the target level of blood pressure control should be <140/90 mm Hg (Recommendation grade: C1, Evidence level: III). In patients with marked stenosis of the bilateral carotid arteries or occlusion of a main trunk of the cerebral arteries, caution against an excessive decrease in blood pressure is particularly necessary (Recommendation grade: C1, Evidence level: V). In patients with lacunar infarction or those taking antithrombotic drugs, a lower level, <130/80 mm Hg, should be targeted if possible (Recommendation grade: C1, Evidence level: III (lacunar infarction), Evidence level: IVb (antithrombotic drugs)).
-
4
Cerebral hemorrhage: In the hyperacute (within 24 h after onset), acute and subacute phases, antihypertensive therapy should be indicated for patients with a systolic blood pressure of >180 mm Hg or a mean blood pressure of >130 mm Hg (Recommendation grade: C1, Evidence level: III). The target of blood pressure control should be 80% of the pretreatment value (Recommendation grade: C1, Evidence level: VI). In the chronic phase, the target of blood pressure control should be <140/90 mm Hg. If possible, a lower level, <130/80 mm Hg, should be targeted (Recommendation grade: C1, Evidence level: VI).
-
5
Subarachnoid hemorrhage: In patients with subarachnoid hemorrhage related to ruptured cerebral aneurysms from onset until the treatment of cerebral aneurysms, antihypertensive therapy should be performed, targeting 80% of the pretreatment value, when the systolic blood pressure exceeds 160 mm Hg (Recommendation grade: C1, Evidence level: VI). In the chronic phase, the target of blood pressure control should be <140/90 mm Hg. If possible, a lower level, <130/80 mm Hg, should be targeted (Recommendation grade: C1, Evidence level: VI).
-
6
In the hyperacute phase of cerebrovascular disease, the i.v. administration of a very low dose of nicardipine, diltiazem, nitroglycerin or nitroprusside is recommended (Recommendation grade: C1, Evidence level: VI). In the acute phase, it should be switched to oral antihypertensive drugs if possible. The sublingual administration of nifedipine should be avoided, because it may induce a rapid decrease in blood pressure (Recommendation grade: D, Consensus, Evidence level: VI).
-
7
Oral antihypertensive drugs such as Ca channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diuretics are recommended for patients with cerebrovascular disease (Recommendation grade: C1, Evidence level: VI).
1. CEREBROVASCULAR DISEASE
In Japan, cerebrovascular disease accounts for a high percentage of patients with hypertensive organ damage, and the number of patients with cerebrovascular disease, particularly those with cerebral infarction, is increasing with the aging of the population. Many patients with cerebrovascular disease develop hypertension in the acute phase, and blood pressure control in the acute phase is an initial problem. In particular, how antihypertensive therapy should be conducted on reperfusion therapy (thrombolytic therapy or intravascular treatment) for cerebral infarction in the hyperacute phase has also become an important clinical issue. Furthermore, hypertension is the most important risk factor involved in the recurrence of cerebrovascular disease, and blood pressure management for the prevention of recurrence is necessary. In hypertensive patients with cerebrovascular disease, subjects to be treated with antihypertensive drugs and the target level of blood pressure control are determined on the basis of the clinical disease type, interval after onset, severity, age, and use of antithrombotic drugs. In addition, as a high percentage of elderly hypertensive patients are known to have asymptomatic cerebrovascular disease, blood pressure management in hypertensive patients with silent cerebrovascular disease is also important. Treatment for hypertension with cerebrovascular disease is summarized in Table 6-1.
1) Hyperacute/acute phases
In the hyperacute phase, within 24 h, and in the acute phase, within 1–2 weeks after the onset of cerebrovascular disease, a high blood pressure is observed regardless of the disease type, cerebral infarction, cerebral hemorrhage or subarachnoid hemorrhage. This increase in blood pressure associated with onset is considered to be a biological protective reaction to stress, urinary retention, headache, brain tissue ischemia and an increase in intracranial pressure due to edema and hematoma. In many patients, blood pressure gradually decreases through resting, urination by bladder catheterization, pain control and treatment of brain edema without the administration of antihypertensive drugs. It begins to decrease within 24 h after onset in most patients with cerebral infarction and within a few days in those with cerebral hemorrhage.536,537
The range of autoregulation of cerebral blood flow is shifted to the right due to hypertension.538 Autoregulation itself disappears in the acute phase of cerebrovascular disease, and cerebral blood flow decreases even with a slight reduction in blood pressure. Thus, lowering blood pressure further reduces local cerebral blood flow in the lesion and in the surrounding penumbra region (area of reversible damage in which functional recovery with restoration of blood pressure is expected), possibly causing enlargement of the lesion (infarction).539 As the ischemic area is in a state of vasoparalysis, vasodilator drugs only dilate blood vessels of the intact areas, with a decrease in blood flow in the lesion, which is called intracranial steal. For these reasons, aggressive antihypertensive treatment is not performed, in principle, in the acute phase of cerebrovascular disease.540
(1) Target level of blood pressure control
Cerebral infarction
In the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) Study,541 patients with cerebral infarction in whom systolic blood pressure (mean value of at least two sessions of blood pressure measurement) was ⩾200 mm Hg or diastolic pressure was ⩾110 mm Hg 6 to 24 h after admission, or in whom systolic blood pressure was ⩾180 mm Hg or diastolic pressure was ⩾105 mm Hg 24 to 36 h after admission, were treated with an ARB, candesartan, for 1 week. Although there was no significant difference in the prognosis of stroke, which was a primary end point, the mortality rate after 1 year and occurrence of cardiovascular events, which were secondary end points, significantly reduced. ARBs were expected to have an organ-protecting effect. However, in the Scandinavian Candesartan Acute Stroke Trial (SCAST),542 cerebrovascular disease patients (primarily, cerebral infarction, ischemia: 85%; hemorrhage: 15%) with a systolic blood pressure of >140 mm Hg within 30 h after onset were randomly divided into candesartan-treated and non-candesartan-treated groups for 7-day administration, and the occurrence of complicated cardiovascular events over 6 months was used as a major evaluation item. The blood pressures on day 7 in the candesartan-treated and non-candesartan-treated groups were 147/82 and 152/84 mm Hg, respectively; in the former, the value was significantly lower. There was no significant difference in the complex end point after 6 months between the two groups. The SCAST Study differs from the ACCESS in the following points: subjects with a relatively lower blood pressure were enrolled, and blood pressure was significantly lower in the treatment group. This suggests that antihypertensive treatment should be carefully administered early after the onset of cerebral infarction.
The JSH2014 Guidelines recommend antihypertensive treatment by i.v. administration if systolic blood pressure is >185 mm Hg or diastolic blood pressure is >110 mm Hg in patients in whom thrombolytic therapy by the i.v. injection of tissue plasminogen activator (t-PA) in the hyperacute phase of cerebral infarction, within 4.5 h after onset, is scheduled according to the Guidelines of the American Stroke Association.536 Systolic and diastolic blood pressures should be controlled at <180 and <105 mm Hg, respectively, by 24-h strict blood pressure management involving blood pressure monitoring during and after treatment.536 Patients in whom endovascular treatment (such as mechanical thrombectomy) is scheduled should also be treated in accordance with thrombolytic therapy.
Even when thrombolytic therapy is not performed, hypertensive encephalopathy, cardiac complications or renal insufficiency may occur in cerebral infarction patients with a systolic blood pressure of >220 mm Hg and a diastolic blood pressure of >120 mm Hg; therefore, the target level of blood pressure control should be 85–90% of the pretreatment value.536
Cerebral hemorrhage
There is no sufficient evidence regarding blood pressure management in patients with cerebral hemorrhage. In the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT) (pilot study) involving patients with cerebral hemorrhage in the hyperacute phase (within 6 h after onset),543 the results were compared between groups with a target systolic blood pressure of <140 mm Hg and <180 mm Hg, and enlargement of hematoma was reduced in the former. However, there was no marked difference in the prognosis. In the INTERACT2 involving 2839 patients with cerebral hemorrhage within 6 h, in which the results were compared between groups with a target systolic blood pressure of <140 mm Hg and <180 mm Hg, the mortality rate or incidence of poor outcome (modified Ranking Scale: 3–6) 90 days after onset, as a major evaluation item, was slightly higher in the group with a target systolic blood pressure of <180 mm Hg. A shift analysis of the modified Ranking Scale 90 days after onset, as an accessory evaluation item, showed that the functional prognosis was significantly more favorable in the group with a target systolic blood pressure of <140 mm Hg.544 According to a survey on current blood pressure management for acute-phase cerebral hemorrhage in Japan,545 systolic blood pressure control at ⩽160 mm Hg by i.v. injection of nicardipine was routinely performed. The results of the SAMURAI-ICH Study, which confirmed the validity of a majority opinion presented in this survey through a multi-center, cooperative, prospective study design, indicated the safety of systolic blood pressure control at 120–160 mm Hg by the i.v. injection of nicardipine in Japanese patients.546 Its subanalysis showed that blood pressure control at a lower level in the target range of 120–160 mm Hg led to a more favorable outcome.547
The JSH2014 Guidelines recommend that antihypertensive treatment should be administered to patients with a systolic blood pressure of >180 mm Hg or a mean blood pressure of >130 mm Hg in the hyperacute (within 24 h after onset) and acute phases of cerebral hemorrhage according to the Guidelines of the American Stroke Association.537 The target of blood pressure control should be 80% of the pretreatment value. In patients with a systolic blood pressure of 150–180 mm Hg, the target blood pressure should be ∼140 mm Hg. However, the effectiveness of decreasing systolic blood pressure to 140 mm Hg or below should be further investigated. In patients in whom an increase in intracranial pressure is expected due to a severe condition, it must be considered that cerebral perfusion pressure may decrease with blood pressure, deteriorating symptoms or causing acute renal insufficiency.
Subarachnoid hemorrhage
In patients with subarachnoid hemorrhage, it is important to prevent additional hemorrhage. Sufficient control of blood pressure, sedation and pain control are desirable. In the Guidelines of the American Stroke Association,548 it is described that antihypertensive treatment should be performed when systolic blood pressure is >160 mm Hg in patients with subarachnoid hemorrhage related to ruptured cerebral aneurysms from onset until the treatment of cerebral aneurysms, and that the target level of blood pressure control should be <160 mm Hg. The JSH2014 Guidelines recommend that the target of blood pressure control should be 80% of the pretreatment value when systolic blood pressure exceeds 160 mm Hg in patients with subarachnoid hemorrhage related to ruptured cerebral aneurysms from onset until the treatment of cerebral aneurysms. However, it must be considered that cerebral perfusion pressure may decrease with blood pressure, deteriorating symptoms, in patients in whom an increase in intracranial pressure is expected due to a severe condition and in those with acute-phase cerebral infarction or cerebrovascular spasm.
(2) Antihypertensive drugs to be recommended
Drugs that act quickly and allow dose adjustment are desirable regardless of the clinical disease type of cerebrovascular disease. Ca channel blockers, such as nicardipine and diltiazem or nitroglycerine and nitroprusside, which have long been used, are administered by low-dose i.v. instillation. However, it must be considered that these drugs may increase the intracranial pressure. Furthermore, the sublingual administration of nifedipine capsules should be avoided, because it may induce a rapid decrease in blood pressure. Antihypertensive treatment by injection should be substituted for oral treatment as early as possible. As oral antihypertensive drugs, Ca channel blockers, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors and diuretics are recommended.
Rehabilitation from an early stage is necessary for improving activities of daily living in stroke patients, but attention must be paid to changes in blood pressure while conducting rehabilitation at the bedside.
2) Subacute phase
In the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study,549 the recurrence rate of stroke, as a primary end point, was followed up for 2.5 years (average) and compared between the telmisartan (ARB, 80 mg per day) and placebo groups in 20 332 patients, aged over 55 years, early (median: 15 days) after the onset of ischemic cerebrovascular disease. In the telmisartan group, the mean blood pressure was 3.8/2.0 mm Hg lower than in the placebo group, but there was no difference in the recurrence rate of stroke. The post hoc analysis550 of the PRoFESS showed that, when the mean systolic blood pressure was controlled at <120 mm Hg in patients with noncardiogenic cerebral infarction, the incidence of stroke events was higher than in those in whom it was controlled at 130–139 mm Hg.
The JSH2014 Guidelines recommend that blood pressure control in the subacute phase of cerebral infarction/hemorrhage, 3 or 4 weeks after onset, should be basically conducted in accordance with that in the acute phase. However, in some patients, blood pressure can be decreased to the level targeted in the chronic phase while evaluating the patient's symptoms. Among patients of cerebral infarction with stable symptoms and systolic blood pressure of 180–220 mmHg in whom stenosis of the carotid artery or of a main trunk of the cerebral arteries is less than 50% and there may be no possibility of hemodynamic cerebral ischemia related to a decrease of blood pressure, attention must be paid of signs of cerebral circulatory insufficiency during antihypertensive therapy. Target of blood pressure should be 85–90% of the pretreatment value.
3) Chronic phase
Patients with a history of cerebrovascular disease are known to frequently develop new cerebrovascular disease, and the control of hypertension, which is its greatest risk factor, is extremely important for the treatment of patients in the chronic phase of cerebrovascular disease. According to the results of a retrospective study in Japan, the relationship between blood pressure after cerebrovascular disease and recurrence rate varies markedly among disease types, and the report of a J-shaped relationship between the recurrence of cerebral infarction and diastolic pressure, which is not observed in patients with cerebral hemorrhage, has attracted attention.551
Since 1990, large-scale studies on the relationship between the prevention of recurrent cerebrovascular disease and blood pressure have been carried out,256,552–557with systematic reviews.558,559 Antihypertensive drug therapy significantly reduces the recurrence rate of all types of cerebrovascular disease, the recurrence rate of nonfatal cerebral infarction, and incidences of myocardial infarction and all vascular events.
(1) Target of blood pressure control
Cerebral infarction
In the Perindopril Protection against Recurrent Stroke Study (PROGRESS),256 perindopril (4 mg per day) or a diuretic, indapamide (2 mg per day), was additionally administered to 6105 patients with chronic-phase cerebrovascular disease, primarily including cerebral infarction (cerebral infarction: 71%; transient cerebral ischemic attacks: 22%; and cerebral hemorrhage: 11%), with a mean age of 64 years, in addition to conventional treatment. The blood pressure decreased from 147/86 to about 138/82 mm Hg, and the recurrence rate of stroke was reduced by 28%. Its subanalysis232 indicated that the incidences of cerebral hemorrhage and cerebral infarction were lower in patients in whom blood pressure was controlled at a lower level (a systolic blood pressure of ∼120 mm Hg).
Rothwell et al.282 reported that the risk of cerebrovascular disease significantly increased in a group in which the systolic blood pressure decreased to 140 mm Hg among patients with symptomatic, 70% or greater stenosis of the bilateral carotid arteries (accounting for 2–3%), whereas there was no increase in this risk even when the systolic blood pressure decreased to 140 mm Hg in patients with 70% or greater unilateral carotid artery stenosis. In the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study,560 among patients with symptomatic intracranial artery (internal carotid, middle cerebral, vertebral or basilar artery) stenosis, the blood pressure level was not associated with the risk for ischemic cerebrovascular disease in those with marked (70% or greater) stenosis. In those with moderate (69% or lower) stenosis, the risk for ischemic cerebrovascular disease was high when the systolic blood pressure was 160 mm Hg or above. Thus, in the presence of obstruction of a main trunk of the cerebral arteries or marked stenosis, management matched to individual patients is necessary. Furthermore, the hemodynamics may differ between vascular stenosis and obstruction. There is little evidence as a reference for the relationship between blood pressure and the risk for ischemic cerebrovascular disease in patients with unilateral obstruction of the internal carotid or basilar artery. Yamauchi et al.561 examined the relationship between blood pressure and recurrent stroke during follow-up with respect to the presence or absence of impaired perfusion on positron emission tomography in patients with symptomatic atherosclerotic occlusion of a main trunk of the cerebral arteries. In patients with impaired perfusion, the risk of recurrent stroke was high when the systolic blood pressure was <130 mm Hg. In those without impaired perfusion, this risk may be high at a high blood pressure level. They concluded that it is important to evaluate the presence or absence of impaired perfusion for blood pressure management.
In the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial,557 a randomized comparative study was conducted on 3020 patients with chronic-phase lacunar infarction by dividing them into two groups: a group with a systolic blood pressure of <130 mm Hg (aggressive therapy group) and that with a systolic blood pressure of 130–149 mm Hg (standard therapy group), with a mean follow-up of 3.7 years. The type of antihypertensive drug was not limited. The mean systolic blood pressures after 1 year in the two groups were 127 and 138 mm Hg, respectively. As a major evaluation item, cerebral infarction/hemorrhage was observed in 152 (2.8%yr) and 125 (2.2%yr) patients in the standard and aggressive therapy groups, respectively; there was no significant difference. Cerebral infarction was present in 131 (2.4%yr) and 112 (2.0%yr) patients, respectively, showing no significant difference. Cerebral hemorrhage was present in 16 (0.29%yr) and 6 (0.11%yr) patients, respectively; its incidence was significantly lower in patients with a lower systolic blood pressure.
In the Bleeding with Antithrombotic Therapy (BAT) Study,325 4009 patients taking antithrombotic drugs for the prevention of recurrent cerebrovascular or heart disease were prospectively enrolled, and hemorrhagic events were investigated over 19 months. Cerebral hemorrhage was observed in 0.3% of patients taking a single antithrombotic drug, 0.6% of those receiving combination therapy with an antiplatelet drug, 0.6% of those taking Warfarin and 1.0% of those receiving a combination of Warfarin and an antiplatelet drug. The onset of cerebral hemorrhage was particularly noted in patients with a history of cerebrovascular disorder. The results suggest that the incidence of cerebral hemorrhage is lower when the blood pressure immediately before/after onset is lower in patients taking antithrombotic drugs, and that blood pressure should be reduced to <130/81 mm Hg.323
The Guidelines of the American Stroke Association562 propose no clear target of blood pressure control or degree of blood pressure reduction and consider that they vary among individual patients. A mean decrease in blood pressure of about 10/5 mm Hg is effective. The JNC7 emphasizes that a normal blood pressure is defined as <120/80 mm Hg.
On the other hand, the ESH/ESC Guidelines revised in 2013120 recommend a systolic blood pressure of <140 mm Hg as a target of blood pressure control for patients in the chronic phase of cerebrovascular disease. They also propose that a higher target level may be established for elderly patients.
In the JSH2014 Guidelines, the target of blood pressure control for patients with chronic-phase cerebral infarction is established as <140/90 mm Hg. In particular, an excessive decrease in blood pressure should be avoided in patients with marked stenosis of the bilateral carotid arteries or occlusion of a main trunk of the cerebral arteries. However, the Guidelines recommend that a lower level (<130/80 mm Hg) should be targeted in patients with lacunar infarction or in those taking antithrombotic drugs (excluding those with 50% or greater stenosis/occlusion of the carotid artery or a main trunk of the cerebral arteries). Complaints of dizziness, light headedness, tiredness, numbness, weakness, loss of energy or exacerbation of neurological signs or symptoms during treatment may be symptoms of cerebral circulatory insufficiency due to a decrease in blood pressure, and a decrease in the dose or change in the type of antihypertensive drug is necessary. Particular caution is needed in patients with occlusion of a main trunk of the cerebral arteries (especially in the vertebral-basilar artery system), because dysautoregulation of the cerebral circulation may persist for 3 months or more.563
Cerebral hemorrhage
With regard to recurrent cerebral hemorrhage, a study reported that a diastolic blood pressure of 75–90 mm Hg was favorable,551 and another study indicated that the recurrence rate was low when diastolic blood pressure was controlled at <90 mm Hg.564 However, the evidence level is low. In the Guidelines of the American Stroke Association,537 the final target of blood pressure control in patients with cerebral hemorrhage (chronic phase) is established as <140/90 mm Hg (diabetes mellitus and chronic kidney disease (CKD): <130/80 mm Hg). The JSH2014 Guidelines recommend that the final target of blood pressure control in patients with cerebral hemorrhage should be <140/90 mm Hg, and that a blood pressure of <130/80 mm Hg should be targeted if possible (excluding patients with 50% or greater stenosis of the carotid artery or a main trunk of the cerebral arteries and those with obstruction).
Subarachnoid hemorrhage
There is no evidence on the target of blood pressure control in the chronic phase of subarachnoid hemorrhage. The target of blood pressure control was established in accordance with that in patients with cerebral hemorrhage.
(2) Recommended classes of antihypertensive drug
In PROGRESS,256 a combination of an ACE inhibitor and a diuretic was suggested to reduce the recurrence rate of cerebrovascular disease and prevent the occurrence of dementia. In the Morbidity and Mortality After Stroke (MOSES) Study,556 primary end points (all deaths and all cardiovascular and cerebrovascular events) and cerebrovascular events (one of the secondary end points) were significantly lower in the ARB (eprosartan) group than in the Ca channel blocker (nitrendipine) group in spite of no difference in blood pressure reduction between two groups.
The Guidelines of the American Stroke Association562 recommend a diuretic alone and a diuretic+ACE inhibitor. Proposing that drugs should be selected for each patient depending on background factors (extracranial obstructive vascular diseases, renal disorders, heart disease and diabetes), they also recommend ARBs and ACE inhibitors for patients with diabetes mellitus or atrial fibrillation. In the 2013 ESH-ESC Guidelines,120 all classes of antihypertensive drugs are recommended, because they consider that most of the benefit obtained from drugs can be ascribed to a decrease in blood pressure. Although differences among drugs are considered to be masked if a strict target of blood pressure control is attained, there are also results indicating differences among drugs despite a similar decrease in blood pressure, such as those shown by MOSES.556
Considering the above evidence, the JSH2014 Guidelines recommend Ca channel blockers, ARBs, ACE inhibitors and diuretics, which are first-choice drugs, regardless of the clinical disease type of cerebrovascular disease for the treatment of hypertension in the chronic phase. These drugs do not reduce cerebral blood flow on a decrease in blood pressure (unless there is an excessive decrease in blood pressure). Furthermore, antihypertensive drugs should be selected, considering the presence or absence of associated disorders such as diabetes mellitus, metabolic syndrome and CKD.
4) Asymptomatic phase
The diagnostic criteria (for brain-dock) issued in 1997565 are used for the diagnosis of asymptomatic cerebrovascular disease. Most of the silent cerebral infarction closely related to hypertension is a small lesion similar to lacunar infarction, a small vessel disease for which hypertension and age are considered to be the greatest risk factors. Its presence and progression are independent risk factors for cerebrovascular disease and impairment of cognitive function.186, 187, 566 Asymptomatic cerebral hemorrhage (microhemorrhage), which is detected mostly by T2-weighted MRI, is attracting attention.567–569
In principle, target of blood pressure and useful antihypertensive drugs for hypertensive patients with silent cerebral infarction or cerebral hemorrhage are the same as those for chronic phase of cerebrovascular disease, but the results of a CT substudy of PROGRESS570 suggested that more antihypertensive treatment is desirable. Silent cerebral infarction is an index of target organ damage along with white matter lesions, and non-dipper, rise and morning surges observed by 24-h blood pressure monitoring are its risk factors.137, 151, 152, 571 Blood pressure control over 24 h and early in the morning is important.
In addition, asymptomatic carotid artery stenosis and unruptured cerebral aneurysms are also frequently detected, and they have been shown to be risk factors for the occurrence of cerebrovascular disease. With regard to asymptomatic carotid artery stenosis, the evaluation of indications for surgical treatment before the initiation of antihypertensive treatment is important. If the patient has a familial history of subarachnoid hemorrhage or unruptured cerebral aneurysm, aggressive antihypertensive treatment is recommended.
In the asymptomatic phase, patients feel high-level anxiety over the condition of cerebrovascular disease and treatment, and hence sufficient informed consent is extremely important.
2. HEART DISEASE
POINT 6b
Coronary artery disease
-
1
In patients with coronary artery disease, it is important to sufficiently reduce blood pressure while paying attention to ischemic symptoms/findings of damages of the heart (Table 6-2). The target of blood pressure control should be <140/90 mm Hg, in principle (Recommendation grade: A, Evidence level: I).
-
2
Hypertension complicated by angina pectoris due to organic coronary artery stenosis is a good indication for Ca channel blockers and β-blockers with no endogenous sympathomimetic action (Recommendation grade: A, Evidence level: I).
-
3
Vasospastic angina pectoris is a good indication for Ca channel blockers (Recommendation grade: B, Evidence level: II).
-
4
In patients with old myocardial infarction, β-blockers, renin–angiotensin (RA) system inhibitors (ACE inhibitors, ARBs) and aldosterone antagonists reduce the mortality rate and improve the prognosis (Recommendation grade: A, Evidence level: I).
Heart failure
-
1
In patients with heart failure, antihypertensive drugs are used not only to reduce blood pressure but also to improve their quality of life and/or prognosis (Recommendation grade: A, Evidence level: I).
-
2
The combination of RA system inhibitor+β-blocker+diuretic is a standard treatment method for heart failure with reduced ejection fraction (HFrEF). It reduces mortality and improves the prognosis. However, RA system inhibitors and β-blockers should be started at low doses, and their doses should be titrated carefully and gradually, to avoid the exacerbation of heart failure, hypotension, bradycardia (β-blockers) and renal dysfunction (Recommendation grade: A, Evidence level: I).
-
3
Aldosterone antagonists further improve the prognosis of patients with severe HFrEF on standard treatment (Recommendation grade: A, Evidence level: I).
-
4
If a decrease in blood pressure is insufficient in patients with HFrEF, a long-acting Ca channel blocker should be added (Recommendation grade: A, Evidence level: I).
-
5
In patients with heart failure with preserved ejection fraction, sufficient antihypertensive treatment is important (Recommendation grade: B, Evidence level: II).
Cardiac hypertrophy
-
1
The regression of cardiac hypertrophy leads to an improvement in prognosis (Recommendation grade: A, Evidence level: I).
-
2
Sustained and sufficient decrease in blood pressure by any antihypertensive drug can induce the regression of cardiac hypertrophy. In particular, RA system inhibitors and Ca channel blockers are effective for cardiac hypertrophy (Recommendation grade: A, Evidence level: I).
The heart is one of the important target organs of hypertension. Increases in systolic and diastolic pressure loads induce myocardial remodeling, such as cardiac hypertrophy and myocardial interstitial fibrosis, and coronary endothelial damage. Risk factors such as dyslipidemia, diabetes mellitus and smoking increase the risk of coronary atherosclerosis and myocardial ischemia. The progression of coronary atherosclerosis and myocardial remodeling leads to coronary artery disease, heart failure, arrhythmia and sudden death.
Atrial fibrillation, of which the incidence has recently increased, markedly increases the risk of cardiogenic cerebral embolism, and the incidence of cardiovascular events and mortality rate increase by about 2.5-fold.572,573 Hypertension is the most important risk factor for new onset of atrial fibrillation.574,575 In particular, left ventricular hypertrophy and left atrial enlargement are independent risk factors for new onset of atrial fibrillation. When antihypertensive treatment leads to the regression of left ventricular hypertrophy, the incidence of atrial fibrillation decreases.576 Furthermore, hypertension also increases the risks of stroke and arterial embolism in patients with chronic atrial fibrillation.577,578
In hypertensive patients with heart disease, the number of those taking antithrombotic drugs (antiplatelet drugs, anticoagulants) has increased. As these drugs increase the incidence of hemorrhagic complications, especially intracranial hemorrhage, strict blood pressure control is necessary in patients taking antithrombotic drugs (see Section 7 of Chapter 3, OTHER POINTS REQUIRING ATTENTION).
Therefore, in hypertensive patients with heart disease, sufficient reduction in blood pressure is mandatory to reduce the cardiovascular mortality rate and incidence of cardiovascular events.237,260,466,579
1) Coronary artery disease
Hypertension increases the incidence of coronary artery disease. However, conventional antihypertensive drug therapy with diuretics and β-blockers does not markedly reduce the incidence of coronary artery disease.580 Recent studies have reported that long-acting Ca channel blockers and RA system inhibitors (ACE inhibitors and ARBs) reduce the incidence of coronary artery disease.446,555,581–583 Furthermore, clinical trials in Japan have suggested that cardiac events can be prevented in patients with coronary artery disease by sufficiently reducing blood pressure using RA system inhibitors or long-acting Ca channel blockers.466,584,585
To prevent the occurrence and progression of coronary artery disease, management of other risk factors in addition to antihypertensive treatment is important. Particularly, the treatment of hypercholesterolemia using 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, antiplatelet therapy with low-dose aspirin and cessation of smoking have been shown to be useful for the primary and, in particular, secondary prevention of coronary events.273,483,586–588
Evidence regarding the target level of blood pressure control in hypertensive patients with coronary artery disease is insufficient. There is also concern that, in these patients, decrease in blood pressure below a certain level causes a reduction in the diastolic coronary perfusion pressure and induces myocardial ischemia, resulting in worsening of the prognosis (J-shaped curve phenomenon). However, these reports were based on retrospective analyses281,589–591and have not been validated. The INVEST retrospective analysis, which suggests the J-shaped curve phenomenon, showed that coronary revascularization reduced a low diastolic blood pressure-related increase in risk by 50% or more.281 A subanalysis of a large-scale registration study (CREDO-Kyoto Registry) including patients after coronary revascularization in Japan indicated that severe arteriosclerosis, CKD and systolic dysfunction rather than a low blood pressure level itself were independent risk factors for cardiovascular mortality, although the crude cardiovascular mortality rate increased in patients with a diastolic blood pressure of <70 mm Hg.592 On the other hand, in the EUROPA, ACTION, CAMELOT and NORMALISE placebo-controlled studies including patients with coronary artery disease, the risk of coronary artery disease was reduced and coronary plaques were regressed when systolic blood pressure was decreased from 140–149 mm Hg to 130–139 mm Hg and from 130–139 mm Hg to 120–129 mm Hg.446,454,581,583 On the basis of the results of the ACTION and JMIC-B trials, the JSH2014 Guidelines recommend that the target level of blood pressure control in patients with coronary artery disease be <140/90 mm Hg.446,585,593 Although evidence is not sufficient, the risk of cardiovascular events is even higher in patients with multiple risk factors such as a history of myocardial infarction, diabetes mellitus, CKD, dyslipidemia, smoking and family history. Therefore, in such patients, a lower level (<130/80 mm Hg) is desirable in the absence of significant coronary artery stenosis, symptoms of myocardial ischemia and ischemic electrocardiographic findings.
(1) Angina pectoris
In hypertensive patients with angina pectoris, Ca channel blockers and β-blockers are the first choice because of their antianginal actions. Angina pectoris is caused by significant coronary stenosis, coronary vasospasm or both. As coronary vasospasm is prevented by Ca channel blockers, they are the first choice for hypertension complicated by angina at rest and rest-and-effort angina.594–596 Both β-blockers and Ca channel blockers are effective for angina on effort due to organic coronary artery stenosis.597,598 In Japan, angina pectoris attributed to coronary vasospasm is frequently observed. As β-blockers have been suggested to exacerbate coronary vasospasm, a Ca channel blocker or a combination of a Ca channel blocker and a β-blocker is recommended when the mechanism of angina pectoris is unclear.
As the antianginal actions of β-blockers are attributable primarily to heart-rate-lowering effects, β-blockers that do not possess endogenous sympathomimetic actions should be selected.599 There is no difference in antianginal effects between β1-selective and nonselective drugs. Furthermore, the blood-pressure-lowering effect of β-blockers is sometimes not enough;600,601 therefore, when a decrease in blood pressure is insufficient, combination therapy with a long-acting Ca channel blocker or an RA system inhibitor is necessary.
Among Ca channel blockers, long-acting dihydropyridine Ca channel blockers and diltiazem sustained-release preparations are recommended, because reflex tachycardia associated with a decrease in blood pressure is observed less frequently and because the time of administration need not be adjusted for the time of occurrence of anginal attacks. With regard to short-acting dihydropyridine Ca channel blockers, a rapid decrease in blood pressure or reflex tachycardia may induce myocardial ischemia in patients with flow-limiting coronary artery stenosis.
In patients with angina pectoris due to significant coronary artery stenosis, coronary revascularization (coronary bypass grafting or percutaneous coronary intervention) is effective for reducing anginal pain and for decreases in cardiac events related to a low diastolic blood pressure.281 Therefore, when patients have chest pain-like symptoms it is advisable to ask cardiologists to evaluate coronary artery stenosis/myocardial ischemia.
(2) Old myocardial infarction
In large-scale clinical studies in Western countries, β-blockers with no endogenous sympathomimetic action were found to significantly reduce the recurrences of myocardial infarction and sudden death in patients with old myocardial infarction.602,603 In particular, β-blockers should be used for the secondary prevention of coronary artery disease in patients with old myocardial infarction associated with systolic dysfunction and in those with myocardial infarction/acute coronary syndrome within 3 years after onset.587,588 In Japan, β-blockers are used less frequently, partly because of concern about coronary vasospasm. However, in patients with old myocardial infarction having significant organic coronary artery lesions, β-blockers are a treatment option. Short-acting Ca channel blockers may increase cardiac accidents, but long-acting Ca channel blockers do not worsen the prognosis.237 In addition, diltiazem reduced the recurrence of myocardial infarction in patients with non-Q-wave infarction without heart failure.604 In follow-up studies of a large number of patients conducted in Japan, both β-blockers and long-acting Ca channel blockers were found to reduce the incidence of cardiac events,585,605–607but short-acting Ca channel blockers tended to exacerbate them608 in patients with old myocardial infarction.
In patients with left ventricular systolic dysfunction after myocardial infarction (ejection fraction: ⩽40%), RA system inhibitors have been shown to prevent left ventricular remodeling (ventricular dilation, myocardial hypertrophy and interstitial fibrosis) and reduce the incidence of heart failure and sudden death.609,610 Ventricular remodeling has an important role in the progression of myocardial damage and in the occurrence/exacerbation of heart failure. Therefore, left ventricular dilation and systolic dysfunction after myocardial infarction are good indications for RA system inhibitors. Many large-scale clinical studies have also indicated that ACE inhibitors decrease the incidence of cardiovascular complications after myocardial infarction, while improving the prognosis; their usefulness in the secondary prevention of myocardial infarction has been established.609,611,612 The Guideline for the Secondary Prevention of Myocardial Infarction published by the Japanese Circulation Society states that, among RA system inhibitors, ACE inhibitors are preferred as a first-choice drug for the secondary prevention of myocardial infarction and that ARBs may be used only when there is no tolerance to ACE inhibitors.483 In patients with a severe systolic dysfunction after myocardial infarction, the prognosis is further improved by the administration of an aldosterone antagonist in addition to an RA system inhibitor, a β-blocker and a diuretic.499,613
2) Heart failure
Epidemiological studies in Western countries have shown that hypertension is the most frequent underlying cause of heart failure, and similar results have been obtained in a patient registration study in Japan.614 Large-scale clinical studies in Western countries have also shown that antihypertensive treatment reduces the incidence of heart failure in hypertensive patients.615
Many patients with heart failure have normal or low blood pressure. Therefore, in patients with heart failure, antihypertensive drugs are not necessarily used for reducing blood pressure but, more importantly, for improving their quality of life, preventing hospitalization due to heart failure and improving the prognosis.
(1) Heart failure with reduced ejection fraction
RA system inhibitors improve the long-term prognosis of chronic heart failure and myocardial infarction and reduce the frequency of hospitalization regardless of the presence or absence of symptoms of heart failure or the degree of left ventricular dysfunction.609–613,616–622 In the Guidelines for the Treatment of Chronic Heart Failure published by the Japanese Circulation Society, it is recommended that, among RA system inhibitors, ACE inhibitors should be initially used to treat heart failure with reduced ejection fraction (HFrEF) and that ARBs should be used when there is no tolerance to ACE inhibitors.447 Treatment with β-blockers should be started at a low dose and doses are titrated gradually with caution. β-blockers improve the prognosis of patients with HFrEF and reduce the frequency of hospitalization regardless of the presence or absence of symptoms.603,623–626Furthermore, diuretics are used for the treatment and prevention of organ congestion. Therefore, combination therapy with an RA system inhibitor, a β-blocker and a diuretic is a standard treatment method for systolic dysfunction.447,627–629Moreover, the addition of an aldosterone antagonist further improves the prognosis of patients with severe HFrEF on the standard treatment.499,613,616
In large-scale clinical studies, the doses of RA system inhibitors and β-blockers that improved the prognosis of heart failure were higher than those used for the treatment of hypertension in Japan. However, as the RA system is activated in heart failure patients, RA system inhibitors exhibit marked hypotensive effects. Therefore, their administration should be started at a low dose (for example, 1/4 to 1/2 of a tablet regardless of the dosage form), and the dose should be gradually increased by confirming the absence of adverse effects such as hypotension and renal dysfunction. In addition, the use of β-blockers should be attempted as much as possible after RA system inhibitors regardless of the severity of heart failure, but utmost caution is necessary at the beginning of their use because β-blockers may exacerbate heart failure. In patients with a reduced systolic function, the administration of β-blockers should be started at a very low dose (1/8 to 1/4 of the dose for hypertension), and the dose should be increased slowly by confirming the absence of heart failure, bradycardia and hypotension.
In hypertensive patients with HFrEF, the treatment of hypertension is important, because hypertension aggravates heart failure by augmenting the left ventricular afterload. In addition, as hypertension promotes left ventricular remodeling and the progression of myocardial damage, hypertension treatment is important for improving the long-term prognosis. Long-acting dihydropyridine Ca channel blockers have been shown not to worsen the prognosis of heart failure patients.237,630,631 Therefore, if a sufficient blood-pressure-lowering effect cannot be obtained with antihypertensive drugs used for the standard treatment of heart failure, a dihydropyridine Ca channel blocker may be added.
(2) Heart failure with preserved ejection fraction
Impairment of diastolic, but not systolic, function is the primary cause of heart failure in nearly a half of the patients hospitalized due to heart failure. Hypertensive heart disease is the most frequent underlying disease for heart failure with preserved ejection fraction (HFpEF), particularly in elderly and female patients.632 In patients with hypertensive heart disease, left ventricular diastolic dysfunction is observed from an early stage due to cardiac hypertrophy and myocardial fibrosis. Therefore, treatment for hypertension is expected to alleviate cardiac hypertrophy and myocardial fibrosis and improve diastolic function. In the EXCEED Study, the improvement in diastolic function was observed in proportion to the degree of decrease in blood pressure obtained by antihypertensive treatment in untreated hypertensive patients with left ventricular diastolic dysfunction.633 In addition, as tachycardia, particularly atrial fibrillation, often induces heart failure, its prevention and appropriate control of the heart rate are important. The possibility of diastolic dysfunction due to latent coronary artery diseases should also be considered. In a randomized study, ARBs did not improve the prognosis of heart failure with HFpEF.634–636 However, a large-scale, prospective study (Swedish Heart Failure Registry) indicated that the total mortality rate was lower in patients taking RA system inhibitors.637
3) Cardiac hypertrophy
Cardiac hypertrophy is caused by pressure load and often regresses through long-term antihypertensive treatment. Epidemiological studies have revealed that cardiac hypertrophy is one of the independent risk factors that determine the prognosis of hypertensive patients. The mortality rate and incidence of cardiac events or heart failure due to coronary artery disease are high in patients with cardiac hypertrophy.638 The incidence of cardiac events and sudden death decreases in patients who show regression of cardiac hypertrophy by antihypertensive treatment compared with those who do not.639,640 The CASE-J subanalysis showed that, when a blood pressure of <130/75–79 mm Hg was achieved in hypertensive patients with left ventricular hypertrophy, the incidence of cardiovascular events could be reduced to the level in those without cardiac hypertrophy.641 Both systolic and diastolic blood pressures are significant factors for cardiac hypertrophy and must be controlled for the treatment of cardiac hypertrophy.
A meta-analysis directly comparing cardiac hypertrophy-regressing effects among various antihypertensive drugs indicated that RA system inhibitors and Ca channel blockers exhibited the most marked effects.405 There are also reports in Japan that a combination use of aldosterone antagonists with ACE inhibitors or ARBs is more effective for regression of cardiac hypertrophy.642,643 However, the most important factor in the regression of cardiac hypertrophy is a sufficient decrease in blood pressure, and hence all drugs used as the first choice today are expected to regress cardiac hypertrophy through sustained control of blood pressure.644,645
3. KIDNEY DISEASE
POINT 6c
-
1
In patients with CKD, risk factors for cardiovascular disease (CVD), such as hypertension and abnormal diurnal changes in blood pressure, are frequently observed, and the risk of cardiovascular accidents is high.
-
2
For the early detection of CKD, urinalysis and calculation of the estimated glomerular filtration rate (eGFR) should be performed in all hypertensive patients. In patients with diabetes mellitus (diabetes (+)), the urinary albumin level should be evaluated using the urinary albumin-to-urinary creatinine (Cr) ratio (mg per g Cr). In those without diabetes mellitus (diabetes (−)), the urinary protein-to-urinary creatinine ratio (gram per g Cr) should be measured when a qualitative test for urinary protein shows (±) or higher, and patients with a value of 0.15 gram per gram Cr or above should be regarded as showing proteinuria (+).
-
3
Target of blood pressure control In diabetes (+) patients, the target of blood pressure control should be <130/80 mm Hg regardless of the presence or absence of albuminuria (Recommendation grade: B, Evidence level: II). In diabetes (−) and proteinuria (−) patients, it should be <140/90 mm Hg (Recommendation grade: A, Evidence level: I). In those with proteinuria (+), it should be <130/80 mm Hg (Recommendation grade: C1, Evidence level: III). In elderly patients, an excessive decrease in blood pressure should be avoided.
-
4
Regarding lifestyle, salt restriction, maintenance of appropriate body weight, smoking cessation and restriction of protein intake in accordance with the renal function should be practiced. Salt intake should be <6 g per day (Recommendation grade: A, Evidence level: I). However, it should not be reduced to <3 g per day (Recommendation grade: C2, Evidence level: IVb).
-
5
When blood pressure exceeds the target level of blood pressure control, antihypertensive drug therapy should be promptly started, in addition to lifestyle modifications.
-
6
First-choice drugs In diabetes (+) patients, RA system inhibitors should be selected regardless of the presence or absence of albuminuria (patients without albuminuria: Recommendation grade: C1, Evidence level: III; patients with albuminuria: Recommendation grade: A, Evidence level: I)). In diabetes (−) and proteinuria (−) patients, RA system inhibitors, Ca channel blockers or diuretics should be selected (Recommendation grade: B, Evidence level: II). In those with proteinuria (+), RA system inhibitors should be selected (Recommendation grade: B, Evidence level: II).
-
7
A decrease in urinary protein level is strongly associated with the prevention of end-stage renal disease. It is important to decrease the urinary protein level as much as possible.
-
8
In advanced CKD patients with a GFR of <30 ml min−1 per 1.73 m2 or in elderly patients with CKD, RA system inhibitors should be started at a low dose. Changes in eGFR and serum K level must be monitored.
-
9
Combination therapy with several antihypertensive drugs is required in many cases. For the use of diuretics, thiazides should be selected if the GFR is 30 ml min−1 per 1.73 m2 or higher, and loop diuretics should be selected if the GFR is less than 30 ml min−1 per 1.73 m2.
-
10
Patients with CKD may develop acute renal dysfunction. They must be instructed to promptly consult a medical doctor if a possibility of dehydration is suspected in such cases as vomiting, diarrhea or fever.
1) Renal function and blood pressure
There is a close association between hypertension and kidneys. The kidney has an important role in the etiology of hypertension. On the other hand, hypertension causes renal dysfunction, leading to CKD. Once CKD develops, hypertension becomes severe, and a vicious circle is established. In CKD patients, abnormalities in the diurnal rhythm of blood pressure, such as the disappearance of a nocturnal decrease, are observed, becoming a risk factor for the onset of CVD. In addition, CKD is complicated by sleep apnea syndrome in a high proportion of patients, exacerbating hypertension.646,647 In addition to treatment for the primary disease of CKD, strict management of blood pressure over 24 h is important.
Renal function declines with age after the 30s, but the rate of age-associated decrease in the GFR estimated from the Japanese health screening data is very low (about 0.3 ml min−1 per year).648 On the other hand, the GFR may decrease at a rate of 4–8 ml min−1 per year in hypertensive patients.649 The Japanese health screening data showed that aging, diabetes mellitus and hypertension were important risk factors for the appearance of proteinuria or for the occurrence of CKD with a GFR of <60 ml min per 1.73 m2.22
In Japan, major primary diseases in patients chronically undergoing dialysis include diabetic nephropathy, chronic glomerulonephritis and nephrosclerosis. The number of patients undergoing chronic dialysis has steadily increased, and diabetic nephropathy and nephrosclerosis are primary causes of this increase. In recent times, the number of patients for whom dialysis has been newly introduced due to chronic glomerulonephritis has decreased.650 Blood pressure and urinary protein levels are known to be strong factors contributing to the onset of end-stage renal disease (ESRD). In a prospective cohort study involving residents, the incidence of ESRD was the lowest in the optimal blood pressure group. It increased with the blood pressure level, and there was no J-shaped phenomenon.21,651
2) Diagnosis of CKD and its significance
Renal dysfunction and proteinuria are known to be risk factors for ESRD,652–655 but they have also recently been found to be strong risk factors for CVD.245,248,249,656–659 In order to prevent the occurrence of ESRD and CVD through the early detection/intervention of renal damages, the concept of CKD was proposed by the National Kidney Foundation in 2002.660 CKD is defined as the presence of findings suggesting renal damages (abnormalities on urinalysis, abnormalities on imaging, or pathological findings) or renal dysfunction with a GFR of <60 ml min−1 per 1.73 m2 for 3 months or more.439,661 According to epidemiological studies involving residents, even mild proteinuria and microalbuminuria were risk factors for CVD,662 and most patients with CKD died of CVD prior to the occurrence of ESRD.657,658 Therefore, the early detection of CKD is important. In all hypertensive patients, the eGFR should be calculated, and urinalysis should be performed. In Japan, urinary albumin measurement is covered by health insurance only in diabetics. In hypertensive patients without diabetes mellitus, the qualitative test of proteinuria is conducted. If the qualitative test shows (±) or higher, proteinuria should be quantitatively evaluated using the urinary protein/urinary creatinine ratio. Patients with a value of 0.15 g per g Cr or more should be regarded as showing proteinuria (+). In the Guidelines, both diabetics with microalbuminuria (30 mg per g Cr or more) and nondiabetics with mild proteinuria (0.15 g per g Cr or more) are regarded as having proteinuria (+). The quantification of urinary albumin/protein is also recommended from the perspective of treatment selection and evaluation of the treatment response.
In patients with CKD, a decrease in GFR and the presence of proteinuria are risk factors for the development of ESRD and CVD, respectively, through independent mechanisms. The risk increases as urinary protein excretion increases and GFR decreases. If the two factors coexist, the risk additively increases.248,249 In the Kidney Disease: Improving Global Outcomes (KDIGO)663 and the Guide for CKD Treatment published by the Japanese Society of Nephrology,439 a heat map to evaluate the risk based on a combination of a decrease in GFR and urinary protein (albumin) excretion was presented.
Primary diseases are involved in the pathophysiology of CKD. Among patients with the same degree of renal dysfunction, the incidence of CVD in patients with hypertensive nephrosclerosis or diabetic nephropathy is higher than in those with chronic glomerulonephritis.664 In the former, even mild proteinuria is a strong risk factor for CVD. In the presence of diabetes mellitus or hypertension, afferent arterioles exposed to high intravascular pressure are initially affected, and, subsequently, the downstream glomeruli are damaged, leading to the appearance of albuminuria.665 Therefore, there may be a close association between proteinuria and lesions of brain-perforating arteries, or coronary artery diseases, because both of these vasculatures are exposed to high intraluminal pressure as in the case of the afferent arterioles.666 Furthermore, the urinary protein level depends on the degree of damage of individual glomeruli and the number of affected glomeruli. If the urinary protein level is higher, a larger number of glomeruli may be markedly damaged. Severely damaged glomeruli would finally become extinct. Therefore, proteinuria is a strong predictive factor for the occurrence of renal insufficiency.
A recent epidemiological study showed that the prevalence of CKD was higher than expected. In Japan, the number of CKD patients is estimated to be ∼13 000 000, accounting for about 13% of the adult population.667 In Japan, with aging of the population, the number of patients with lifestyle-related diseases such as obesity, hypertension and diabetes mellitus is increasing. Thus, the early detection, treatment and prevention of CKD are important.
3) Diabetic nephropathy (CKD with diabetes mellitus)
Diabetic nephropathy is the leading cause for initiation of dialysis in Japan, accounting for about 40% of new dialysis cases.650 Nephropathy is considered to be present in about 40% of diabetics in Japan.668 Some diabetics show a normal urinary albumin level but have a GFR of <60 ml min−1 per 1.73 m2.669 There are many patients with type 2 diabetes and hypertension. When hypertensive nephrosclerosis is a primary lesion, the urinary protein level is relatively low. Albuminuria has been found to have a particularly important role in the onset of renal insufficiency or CVD in CKD patients with diabetes mellitus. Urinary albumin should be quantitatively evaluated regularly using its ratio to urinary creatinine and used as an index of treatment.
Recently, it has also been shown in Japan that the progression of nephropathy can be prevented and its remission or regression achieved by intensive treatment, and that the remission or regression of diabetic nephropathy is closely related to the prevention of CVD as well as renal insufficiency.670 INNOVATION463 indicated that, in addition to a sufficient reduction in blood pressure, the administration of RA system inhibitors was necessary for inducing remission and regression. ARBs at a high dose are particularly effective for advanced microalbuminuria with a urinary albumin level of 100–299 mg per g Cr.463,671 The doses of RA system inhibitors should be increased using urinary albumin excretion as an index, while monitoring changes in the renal function.
4) Lifestyle modifications
An inappropriate lifestyle is the most important reason for the present increase in CKD patients. Obesity and an excessive salt intake accelerate kidney damage by mechanisms dependent on and independent of blood pressure. Lifestyle modifications are the most basic and important factors in the treatment of CKD, in which restricting salt intake, maintaining an appropriate body weight, cessation of smoking and restricting protein intake are essential.
Restriction of salt intake is important for controlling blood pressure and for preventing the progression of renal dysfunction. As salt sensitivity is often enhanced in hypertensive patients with CKD, restriction of salt intake would be effective for reducing blood pressure. Salt restriction enhances the hypotensive and antiproteinuric effects of ACE inhibitors and ARBs.672 A subanalysis of a study involving patients with diabetic nephropathy showed that the incidences of ESRD and CVD decreased in the low salt intake group, whereas they increased in the extremely low salt intake group.673 The REIN Study indicated that the renoprotective effects of salt restriction were closely associated with a decrease in the urinary protein level.674 On the basis of these results, salt intake should be restricted to <6 g per day (Grade A). However, salt restriction to <3 g per day should be avoided (Grade C2). It is important to promote salt restriction step by step while monitoring blood pressure and urinary protein excretion. In particular, caution is needed in elderly patients.
Abdominal obesity is involved in the development of ESRD or proteinuria.372,675,676 As a risk factor for CKD, body weight changes are important rather than body weight itself.677 Weight loss achieved by interventions reduces albuminuria,678,679 but no interventional study has yet investigated its long-term effects on renal function. Several studies have reported that abdominal obesity is significantly associated with the total mortality rate and incidence of CVD in CKD patients with an eGFR of 30 ml min−1 per 1.73 m2 or higher.680,681 On the other hand, the relationship between obesity and prognosis remains to be clarified in CKD patients with an eGFR of <30 ml min−1 per 1.73 m2. Thus, in CKD patients with an eGFR of 30 ml min−1 per 1.73 m2 or higher, decreases in body weight/visceral fat induced by a decrease in energy intake may prevent the progression of CKD, improving the prognosis; thus, weight reduction is recommended in obese patients (Grade C1). However, sufficient guidance should be conducted so that excessive dietary restrictions may not result in a deficiency of essential nutrients, such as vitamin.
Smoking has been reported to exert adverse effects on proteinuria and renal dysfunction in both diabetic and nondiabetic nephropathy patients.682,683 It has been established that smoking is a risk factor for CVD. Considering that the risk of cardiovascular death is high in CKD patients, smoking cessation is crucial.
A study indicated that restriction of protein intake decreased the incidence of ESRD and relative risk of death.684 However, restriction of protein intake does not influence the rate of reduction in GFR, although it prolongs the interval until renal replacement therapy is required.685–687 Strict restriction of protein intake induces various risks. In particular, in elderly patients with a low urinary protein level, the rate of reduction in renal function is essentially slow, and restriction of protein intake is not clinically relevant. Therefore, uniform guidance for restriction of protein intake is inappropriate, and guidance should be performed by comprehensively evaluating individual patients’ conditions, risks and adherence. As standard treatment, protein intake is restricted to 0.6–0.8 g per kg standard body weight per day, but protein restriction may be started at 0.8–1.0 g per day in patients with mild renal dysfunction.439,661
There is insufficient evidence on exercise therapy, but guidance should be given in accordance with the renal function.688 Even in CKD patients with a GFR of <60 ml min−1 per 1.73 m2 (including those undergoing dialysis), exercise therapy reduces blood pressure and central blood pressure and enhances cardiopulmonary functions, improving the quality of life. However, it does not influence the occurrence of CVD or rate of reduction in renal function.689 On the other hand, exercise may increase the incidence of adverse events in CKD patients with a GFR of <60 ml min−1 per 1.73 m2. Therefore, in CKD patients, exercise therapy should be performed after sufficiently understanding the individual's clinical background. However, excessive exercise restriction should be avoided because it induces obesity and affects blood glucose/blood pressure control.
5) Treatment with antihypertensive drugs
The objective of antihypertensive treatment in CKD patients is to inhibit or prevent the progression of renal dysfunction and to prevent the occurrence or recurrence of CVD by reducing blood pressure. For this treatment, it is important to establish the most appropriate target level of blood pressure control for individual patients and perform adequate, individual-matched antihypertensive treatment, considering the patient's background (age, complications and daily environment). From the perspective of simultaneous brain/heart/kidney protection, the following points should be targeted: (1) achieving the target of blood pressure control and (2) reducing or, if possible, normalizing urinary protein (albumin) excretion. To achieve these objectives, combination therapy with RA system inhibitors is necessary in many cases. On the other hand, many CKD patients are elderly and often have complications, such as diabetes mellitus and sclerotic lesions of the coronary artery/cerebral blood vessels/renal artery; in these patients, RA system inhibitors or diuretics may induce an excessive decrease in blood pressure or acute renal dysfunction. To avoid such adverse events and achieve effective antihypertensive treatment, it is essential for individual patients to practice home blood pressure measurement and understand the treatment being received as well as the symptoms associated with its adverse effects. In particular, attention must be paid to the rate of decrease in blood pressure in elderly patients, and an excessive decrease in blood pressure should be avoided.
There is much evidence that antihypertensive treatment prevents the progression of CKD and reduces the risk of CVD and death. To prevent the progression of CKD and occurrence of CVD, strict, 24-h blood pressure control is essential. In the JSH2009 Guidelines, the target of blood pressure control in CKD patients was established as <130/80 mm Hg, and as <125/75 mm Hg if the urinary protein level is 1 g per day or higher. However, recently, the opinion that ‘there is no positive reason for lowering blood pressure to <130/80 mm Hg’ was reported by the ESH through a reassessment of clinical studies.690 In addition, a J-shaped phenomenon in which the incidence of myocardial infarction and mortality rate increase with an excessive decrease in blood pressure may occur in patients with coronary artery disease (ischemic heart disease).284,285 Based on this background, the ESH/ESC 2013 Guidelines recommend the target of blood pressure control in CKD patients to be <140/90 mm Hg, and only when overt proteinuria is present may a systolic blood pressure of 130 mm Hg be targeted while monitoring changes in the GFR.120
The targets of blood pressure control and first-choice drugs in the Guidelines are shown in Table 6-3. This target of blood pressure control reflects that the incidence of stroke is high in Japanese patients with CKD, that the risk of CVD is high in diabetics and that the presence of proteinuria is a strong risk factor for ESRD and CVD. Antihypertensive drug therapy should be promptly started with lifestyle modifications if blood pressure exceeds the target of blood pressure control. Even when the blood pressure level is high-normal, treatment with RA system inhibitors should be started to reduce the urinary protein (albumin) level while monitoring blood pressure and urinary protein.
The results of the ADVANCE and observational studies in Japan have suggested that reducing blood pressure to <130/80 mm Hg in diabetic patients prevents the progression of CKD.691,692 On the other hand, in the ACCORD Study, albuminuria was markedly reduced in the strict blood pressure control group, but the eGFR was more favorably maintained in the standard blood pressure control group.285 With respect to the level of blood pressure control and CVD, the IDNT Study indicated that the total mortality rate was the lowest in patients with a systolic blood pressure of 121–130 mm Hg and that it increased in those with a systolic blood pressure of 120 mm Hg or below.693 On the other hand, a meta-analysis of 13 interventional studies including the ACCORD Study showed that there were no preventive effects of strict blood pressure control on composite outcomes of CVD events, whereas it prevented stroke.258 According to the CASE-J641 and Challenge-DM694 Studies, the occurrence of CVD was lowest in the group in which a clinic blood pressure of <130/80 mm Hg was achieved.
The target of blood pressure control in CKD patients without diabetes mellitus should be <140/90 mm Hg in the absence of proteinuria and <130/80 mm Hg in its presence. Only a limited number of studies, such as the AASK,695 MDRD696 and REIN-2,697 have examined the relationship between the level of blood pressure control and renal events in CKD patients without diabetes mellitus. There were no differences in composite renal end points between the standard and strict blood pressure control groups. In the KEEP Observational Study involving CKD patients with an eGFR of <30 ml min−1 per 1.73 m2, the incidence of ESRD was the lowest in patients with a systolic blood pressure of 130–140 mm Hg.698 On the basis of these results, blood pressure should be maintained at <140/90 mm Hg from the perspective of the prevention of CKD progression (Grade A). On the other hand, subanalyses of the AASK and MDRD studies and follow-up studies after the completion of these studies showed that strict blood pressure control retarded deterioration of renal function only in patients with proteinuria.699–702 Furthermore, a meta-analysis of 11 randomized studies also indicated that strict blood pressure control was useful for reducing the rate of decline in renal function in patients with proteinuria.703 In an observational study in Japan, which examined the relationship between the occurrence of CVD and blood pressure level in CKD patients, the incidences of CVD in the high-normal blood pressure and normotensive groups were lower than those in the hypertensive group.32 In the ARIC and CHS Studies involving CKD patients with an eGFR of 15–60 ml min−1 per 1.73 m2, the risk of stroke was the lowest in patients with a systolic blood pressure of 120–129 mm Hg, and it increased in those with a systolic blood pressure of <120 mm Hg and ⩾130 mm Hg.704 On the other hand, in the PROGRESS Study, a subanalysis of CKD patients (defined on the basis of eGFR alone) showed that the recurrence of stroke was more markedly inhibited in patients in whom a lower target level of blood pressure control was achieved regardless of baseline blood pressure.705 Furthermore, a subanalysis of CASE-J indicated that the incidence of CVD was the lowest in patients in whom blood pressure was controlled at <130/80 mm Hg. These results are based on observational studies or subanalyses, and the evidence level is not high. However, considering that the incidence of stroke is high in the Japanese population, and that proteinuria is a risk factor for stroke independent of renal function,706 the target of blood pressure control in proteinuria (+) patients is established as <130/80 mm Hg in the Guidelines from the perspective of kidney protection and CVD prevention (Recommendation grade: C1).
CKD patients show abnormal diurnal changes in blood pressure. Nighttime hypertension is a risk factor for the progression of CKD and occurrence of CVD. These patients must be instructed to measure home blood pressure in the morning and at night, and, if necessary, ABPM should be performed. Antihypertensive therapy should be conducted prudently by adjusting the time of dosing. Moreover, if diurnal changes are present, screening of sleep apnea syndrome is necessary. If it is present, treatment should be performed.
Proteinuria not only indicates glomerular or vascular damage but is also considered to exacerbate the renal function. In patients with proteinuria, RA system inhibitors may particularly exhibit organ-protecting effects695,707,709 and are selected as a first-choice drug. To sufficiently decrease urinary protein excretion, it is necessary to adjust the doses of ACE inhibitors or ARBs in addition to strict blood pressure control. A subanalysis of CASE-J also showed that ARBs more markedly prevented the onset of CVD and renal events compared with Ca channel blockers in CKD patients with an eGFR of 15–30 ml min−1 per 1.73 m2. With regard to renoprotective effects, ARBs were more advantageous only in patients with proteinuria.709 On the other hand, the efficacy of RA system inhibitors has not been established in CKD patients without proteinuria, and RA system inhibitors, Ca channel blockers or diuretics may become a first-choice drug. For the use of diuretics, thiazide diuretics should be selected in patients with a GFR of 30 ml min−1 per 1.73 m2 or higher, and loop diuretics should be selected in those with a GFR of <30 ml min−1 per 1.73 m2.
RA system inhibitors can be administered to patients with CKD regardless of the stage, but rapid deterioration of the renal function or hyperkalemia is observed in some elderly patients or CKD patients with a GFR of <30 ml min−1 per 1.73 m2. Therefore, administration should be started at a low dose, and the renal function and serum K level must be closely monitored. Usually, RA system inhibitors slowly exhibit hypotensive effects, and there is no rapid decrease in blood pressure after administration. If there is a rapid decrease in blood pressure, this may be associated with dehydration, excessive salt restriction, high-dose therapy with diuretics or renal artery stenosis. To detect a rapid decrease in blood pressure, home blood pressure measurement is effective. If an excessive decrease in blood pressure (systolic blood pressure: 30 mm Hg or greater) is noted immediately after administration, its etiology must be evaluated, and the patient should be referred to a specialist if necessary.
RA system inhibitors ameliorate glomerular hypertension/hyperfiltration by reducing the systolic blood pressure and dilating the efferent arterioles, and therefore the GFR may decrease occasionally. However, this decrease is a reflection of functional change rather than the progression of renal tissue damage, because the GFR returns to its previous level on discontinuing the drug.710 As there is also a report that in those whose renal function, renal function declined temporarily shortly after the beginning of the administration was well maintained over a long period thereafter, careful observation is recommended when an initial increase in the serum creatinine level is mild (rate of decrease in the GFR: <30%). As a decrease in renal function usually becomes apparent within a few days after commencing administration, the serum creatinine level should be measured before and 2 weeks (1 week if possible) after the first administration. If exacerbation of renal function is noted, its causes, such as bilateral renal artery stenosis, should be sought. An increase in the serum K level may also be observed, and its treatment comprises the concomitant use of a diuretic or administration of sodium bicarbonate. The administration of nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided, because they exacerbate renal function and increase the serum K level. Added to this, as ACE inhibitors are excreted via the kidney, with some exceptions, their dose adjustment is necessary in patients with reduced renal function. However, dose adjustment is mostly unnecessary for ARBs, which are excreted via the bile.
In many patients with CKD, multiple-drug combination therapy is necessary to achieve the target blood pressure.649 In the ACCOMPLISH Study, the incidence of renal events in patients undergoing combination therapy with an ACE inhibitor and a long-acting Ca channel blocker was lower than in those undergoing combination therapy with an ACE inhibitor and a thiazide diuretic.438 A CKD subanalysis of the OSCAR Study involving elderly patients showed that, compared with the ARB alone at an increased dose, a combination therapy of an ARB and a Ca channel blocker resulted in better blood pressure control and a low incidence of CVD.711 Ca channel blockers have various characteristics. Clinical studies have indicated that the urinary protein-decreasing effects of some Ca channel blockers are similar to those of ACE inhibitors.712–714 Other studies reported that, when added to RA system inhibitors, the antiproteinuric effect differed among Ca channel blockers.430,452,715 On the other hand, diuretics are required in advanced CKD patients in whom body fluid management is difficult. The principal strategy of body fluid management is salt restriction. Diuretics should be administered at doses as low as possible. In the case of intensive treatment with diuretics, caution should be taken against electrolyte abnormalities, such as hypokalemia, or dehydration. Thus, Ca channel blockers are generally recommended as a drug to be combined with an RA system inhibitor, but, if an excessive volume of body fluid such as edema is observed, low-dose diuretics should be predominantly used. If blood pressure does not reach its target level despite a combination of two drugs, combination therapy with three drugs, an RA system inhibitor, a Ca channel blocker and a diuretic, should be performed, or the doses of an RA system inhibitor and a Ca channel blocker should be increased. If the target of blood pressure control is not achieved despite these approaches, the patient should be regarded as having resistant hypertension (see the corresponding chapter) and referred to a specialist if necessary.
It has been reported that combination therapy with an ARB and an ACE inhibitor reduces the urinary protein level. However, this combination may increase the risk of acute renal dysfunction; thus, caution is needed. Although aldosterone antagonists decrease the urinary protein level,716,717 they increase the risk of hyperkalemia when combined with RA system inhibitors. Therefore, this combination therapy should be carefully performed at a very low dose while monitoring the serum K level. Eplerenone is contraindicated for patients with diabetic nephropathy and for nondiabetic CKD patients with a Ccr of <50 ml min−1 per 1.73 m2.
Direct renin inhibitor (DRI) increases the renal blood flow. The additional administration of this drug to patients with overt diabetic nephropathy receiving high-dose ARB therapy reduces urinary albumin excretion without decreasing the eGFR.489 However, evidence regarding DRI is insufficient in hypertensive patients with CKD. Recently, the results of the ALTITUDE Study, in which a DRI, aliskiren, was additionally administered to high-risk nephropathy patients with type 2 diabetes taking RA system inhibitors at a high dose, were published.490 There were no differences in the incidence of CVD or renal end points between the aliskiren and placebo groups. In the former, adverse events were more frequent. On the basis of the results of the study, combination therapy with a DRI and other RA system inhibitors is generally contraindicated for diabetic nephropathy and nondiabetic CKD patients with an eGFR of <60 ml min−1 per 1.73 m2. This combination may only be selected under a specific condition (when blood pressure control is not sufficient).
6) Patients undergoing dialysis
In patients undergoing hemodialysis, there is little evidence regarding the appropriate target of blood pressure control or selection of antihypertensive drugs. Moreover, blood pressure measurement has not been standardized. In patients undergoing hemodialysis, the relationship between blood pressure level and prognosis markedly differs from that in the general population, showing a U-shaped pattern. The mortality rate was the lowest in patients with a systolic blood pressure of 120–160 mm Hg before dialysis.718–721 Malnutrition is not uncommon in patients treated with maintenance hemodialysis, and the incidence of complications such as heart failure is high. The association between blood pressure alone and prognosis is difficult to clarify.722 In addition, a study reported that there were marked changes in blood pressure related to hemodialysis and that a decrease in blood pressure during dialysis and the presence of orthostatic hypotension immediately after dialysis were independent risk factors for total mortality.723
The primary mechanism for hypertension in patients undergoing dialysis is an excessive volume of body fluid. Therefore, it is most important to optimize the dry weight (body weight at which there are minimal signs or symptoms of hypovolemia or hypervolemia), which is measured by a dialysis specialist, and reduce weight gain between dialysis points.724 In patients undergoing dialysis, blood pressure changes periodically, as the body fluid volume decreases on every session of dialysis and the body weight increases before the subsequent dialysis. There are various measurement points of blood pressure: before dialysis, during dialysis, after the completion of dialysis, on standing after its completion, and average weekly blood pressure.725 Blood pressure assessment, involving nondialysis days, not only in the dialysis room but also at home is important.
Thus, blood pressure is exposed to a specific environment in patients undergoing dialysis, and blood pressure management is basically performed by dialysis specialists. The ‘Guidelines for the Evaluation and Treatment of Cardiovascular Complications in Patients on Hemodialysis’ were prepared by the Japanese Society for Dialysis Therapy, describing blood pressure measurement in patients undergoing dialysis, the target of blood pressure control, timing of the administration of antihypertensive drugs and selection of antihypertensive drugs.726 Therefore, currently, dialysis specialists manage blood pressure in accordance with individual dialysis patients’ conditions according to the guidelines, and consult specialists if necessary.
4. VASCULAR DISEASES
POINT 6d
Vascular diseases
-
1
Acute aortic dissection requires immediate blood pressure reduction and pain control. The systolic blood pressure should be controlled at 100–120 mm Hg (Recommendation grade: C1, Evidence level: III).
-
2
In patients with chronic aortic dissection, the target of systolic blood pressure control should be 130 to <135 mm Hg (Recommendation grade: C1, Evidence level: VI).
-
3
In patients with atherosclerotic peripheral arterial disease, a supervised exercise training program is recommended. Added to this, intensive risk factor management including strict control of blood pressure is expected to reduce the concurrence of cardiovascular events.
1) Aortic aneurysm
(1) Aortic dissection
Acute aortic dissection is a hypertensive emergency that requires immediate blood pressure reduction, control of the heart rate, pain control and complete rest. The site and morphology of dissection and the presence or absence of peripheral circulatory disorders due to stenosis/obstruction of arteries branching from the aorta should be evaluated continuously and carefully. As a rule, surgery should be promptly performed to treat Stanford type A dissection, and drug therapy should be administered to treat Stanford type B dissection.727
For blood pressure control, systolic blood pressure should be maintained at 100–120 mm Hg by the continuous infusion of a Ca channel blocker (nicardipine, diltiazem), nitroglycerin or nitroprusside in combination with a β-blocker, but there is no evidence regarding the target systolic blood pressure or effects of combination therapy with a β-blocker.727 When combining diltiazem with a β-blocker, bradycardia must be considered.
There is no established evidence regarding the target systolic blood pressure or selection of antihypertensive drugs in patients with chronic aortic dissection. However, several studies have indicated that β-blockers decrease the number of dissection-associated accidents such as admission,728,729 and others have reported that ACE inhibitors prevent the rupture of abdominal aortic aneurysms.730 To prevent re-dissection or rupture, the target systolic blood pressure should be 130 to <135 mm Hg.731
(2) Aortic aneurysm
As aortic aneurysm is asymptomatic in most patients, it is often detected incidentally on health screening or on examination for other diseases. However, once it ruptures, the mortality rate is very high, and even if patients come to the hospital in a stage of threatened rupture the survival rate is low because of unstable hemodynamics.732
Strict antihypertensive treatment for thoracic aortic aneurysm is important, and systolic blood pressure should be maintained at 105–120 mm Hg, although no evidence regarding the target of blood pressure control has been established. As for the selection of antihypertensive drugs, there is a report of a randomized controlled trial in which the administration of β-blockers was effective for the prevention of aneurysm enlargement in patients with Marfan's syndrome.733 Recently, a cohort study reported that ARBs were useful for inhibiting an increase in the aneurysmal diameter in 18 children with Marfan's syndrome.734
However, there is no established evidence regarding the effects of strict antihypertensive therapy or β-blockers on abdominal aortic aneurysm. In patients admitted with a diagnosis of abdominal aortic aneurysm, the frequency of ruptured aneurysm was reported to be significantly lower in those who received ACE inhibitors before admission in a recent large-scale case-controlled study.730 Undoubtedly, atherosclerosis is closely associated with the etiology of abdominal aortic aneurysm. Whereas the effectiveness of internal treatment for the prevention of enlargement or rupture of aneurysm has not been confirmed by large-scale randomized controlled studies, the importance of smoking cessation has been reported.735
Ultrasonography is useful for the diagnosis of abdominal aortic aneurysm. In addition, it is also useful for evaluating the aneurysmal diameter. If there is a slight increase in the aneurysmal diameter, surgery should be considered at an appropriate time.736
2) Atherosclerotic peripheral arterial disease
Peripheral circulatory disorders due to atherosclerotic vascular lesions are classified according to their severity into Fontaine grade I (no symptom, numbness, coldness), grade II (intermittent claudication), grade III (pain at rest) and grade IV (gangrene/ischemic ulcer). The objectives of treatment are the alleviation of symptoms of ischemia and prevention of cardiovascular events, which often complicate peripheral circulatory disorders. Systematic execution of an exercise program under supervision has been reported to be effective for alleviating ischemic symptoms in the lower limbs.737 Strict blood pressure control is more important for preventing cardiovascular events rather than for improving ischemic symptoms in the lower limbs.738 Therefore, appropriate antihypertensive drugs should be selected according to the complications or patient's conditions that require careful use of drugs (see Chapter 5, Treatment with antihypertensive drugs). The administration of ACE inhibitors to patients with symptomatic atherosclerotic peripheral arterial disease has been reported to have suppressed cardiovascular events by about 25% in a large-scale randomized controlled study.556 β-Blockers have been considered to exacerbate ischemic symptoms in the lower limbs; however, their safe use has been reported in a randomized study involving patients with intermittent claudication.739,740 They can be used in patients with heart failure or coronary artery disease, which often complicate atherosclerotic peripheral arterial disease. Physicians should refer patients with severe atherosclerotic peripheral arterial disease to a specialist, because percutaneous transluminal angioplasty or surgical circulatory reconstruction is required in some cases.
Citation Information
We recommend that any citations to information in the Guidelines are presented in the following format:
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014). Hypertens Res 2014; 37: 253–392.
Please refer to the title page for the full list of authors.
References
Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S . Blood pressure predicts risk of developing end-stage renal disease in men and women . Hypertension 2003 ; 41 : 1341 – 1345 . E-Ib
Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A . Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study . Kidney Int 2007 ; 71 : 159 – 166 . E-Ib
Ninomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A, Ohashi Y, Ueshima H . Japan Arteriosclerosis Longitudinal Study Group . Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study . Circulation 2008 ; 118 : 2694 – 2701 . E-Ia
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F . The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens 2013 ; 31 : 1281 – 1357 GL
Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K . Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study . Circulation 2003 ; 107 : 1401 – 1406 . E-Ib
Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K . Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers . Hypertension 1996 ; 27 : 130 – 135 . E-II
Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K . Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives . Hypertension 2001 ; 38 : 852 – 857 . E-Ib
Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S . Subcortical silent brain infarction as a risk factor for clinical stroke . Stroke 1997 ; 28 : 1932 – 1939 . E-Ib
Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM . Rotterdam Scan Study . Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study . Stroke 2003 ; 34 : 1126 – 1129 . E-Ib
Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B . PROGRESS Collaborative Group . Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial . J Hypertens 2006 ; 24 : 1201 – 1208 . III
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . The Antihypertensive and Lipid-Lowering Treatment t o Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ( ALLHAT) . JAMA 2002 ; 288 : 2981 – 2997 . II
Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M . Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study . Kidney Int 2005 ; 68 : 228 – 236 . E-Ib
Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsune K, Hoshi H, Ito S, Imai Y . Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study . Nephrol Dial Transplant 2007 ; 22 : 1910 – 1915 . E-Ib
Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T . The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population . Kidney Int 2006 ; 69 : 1264 – 1271 . E-Ib
PROGRESS Collaborative Group . Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or ransient ischaemic attack . Lancet 2001 ; 358 : 1033 – 1041 . II
Bangalore S, Kumar S, Lobach I, Messerli FH . Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials . Circulation 2011 ; 123 : 2799 – 27810 . I
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B . Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management o f Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens 2007 ; 25 : 1105 – 1187 GL
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S . HOT Study Group . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial . Lancet 1998 ; 351 : 1755 – 1762 . II
Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ . Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? . Ann Intern Med 2006 ; 144 : 884 – 893 . E-Ib
Rothwell PM, Howard SC, Spence JD . Carotid Endarterectomy Trialists’ Collaboration . Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease . Stroke 2003 ; 34 : 2583 – 2590 . E-Ia
Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S . ONTARGET investigators . Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study . J Hypertens 2009 ; 27 : 1360 – 1369 . III
Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT . Gerstein HCIsmail-Beigi F, ACCORD Study Group . Effects of intensive blood-pressure control in type 2 diabetes mellitus . New Engl J Med 2010 ; 362 : 1575 – 1585 . II]
Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K . Bleeding with Antithrombotic Therapy (BAT) Study Group . Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study . Stroke 2008 ; 39 : 1740 – 1745 . E-Ib
Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K . Bleeding with Antithrombotic Therapy (BAT) Study Group . Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study . Stroke 2010 ; 41 : 1440 – 1444 . V
Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD . Obesity-related glomerulopathy: an emerging epidemic . Kidney Int 2001 ; 59 : 1498 – 1509 . E-II
Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE . A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension . Am J Med 2003 ; 115 : 41 – 46 . I
Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K . Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease (CARTER) Study Investigators . Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin–angiotensin inhibition in hypertensive patients with chronic renal disease . Kidney Int 2007 ; 72 : 1543 – 1549 . II
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA . ACCOMPLISH Trial investigators . Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial . Lancet 2010 ; 375 : 1173 – 1181 . III
Japanese Society of Nephrology . Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012 (in Japanese) . Japanese Society of Nephrology: Tokyo, 2012 . GL
Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA . ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators . Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial . J Hypertens 2005 ; 23 : 641 – 648 . III
The Japanese Circulation Society . Guideline for Treatment of Chronic Heart Failure (JCS 2010) (in Japanese) . The Japanese Circulation Society: Tokyo, 2010 . GL
Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M . Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria . Hypertens Res 2011 ; 34 : 268 – 273 . II
Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE . Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis . J Am Coll Cardiol 2006 ; 48 : 833 – 838 . IVa
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S . INNOVATION Study Group . Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes . Diabetes Care 2007 ; 30 : 1577 – 1578 . II
Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T . Candesartan Antihypertensive Survival Evaluation in Japan Trial Group . Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial . Hypertension 2008 ; 51 : 393 – 398 . II
Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011) . The Japanese Circulation Society 2011, .GL
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK . AVOID Study Investigators . Aliskiren combined with losartan in type 2 diabetes and nephropathy . New Engl J Med 2008 ; 358 : 2433 – 2446 . II]
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA . ALTITUDE Investigators . Cardiorenal end points in a trial of aliskiren for type 2 diabetes . New Engl J Med 2012 ; 367 : 2204 – 2213 . II
Ezekowitz JA, McAlister FA . Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials . Eur Heart J 2009 ; 30 : 469 – 477 . I
Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan Jr PW, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H . American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology . Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association . Stroke 2013 ; 44 : 870 – 947 . GL
Morgenstern LB, Hemphill 3rd JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES, Greenberg SM, Huang JN, MacDonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ . American Heart Association Stroke Council and Council on Cardiovascular Nursing . Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association . Stroke 2010 ; 41 : 2108 – 2129 . GL
Kuriyama Y . CBF (cerebral blood flow) autoregulation and antihypertensive treatment . In: Saruta T (ed). ACE inhibitors; innovative clinical applications (in Japanese) Medical Tribune: Tokyo, 1990, pp 89 – 96 . VI
Bath P, Chalmers J, Powers W, Beilin L, Davis S, Lenfant C, Mancia G, Neal B, Whitworth J, Zanchetti A . International Society of Hypertension Writing Group . International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke . J Hypertens 2003 ; 21 : 665 – 672 . GL
Osaki Y, Matsubayashi K, Yamasaki M, Okumiya K, Yoshimura K, Yoshimura K, Hamashige N, Doi Y . Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke . Hypertens Res 1998 ; 21 : 169 – 173 . E-II
Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P . Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group . The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors . Stroke 2003 ; 34 : 1699 – 1703 . II
Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E . SCAST Study Group . The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial . Lancet 2011 ; 377 : 741 – 750 . II
Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J . . Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial . Lancet Neurol 2008 ; 7 : 391 – 399 . II
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J . : INTERACT2 Investigators . Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage . New Engl J Med 2013 ; 368 : 2355 – 2365 . II
Koga M, Toyoda K, Naganuma M, Kario K, Nakagawara J, Furui E, Shiokawa Y, Hasegawa Y, Okuda S, Yamagami H, Kimura K, Okada Y, Minematsu K . Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) Study Investigators . Nationwide survey of antihypertensive treatment for acute intracerebral hemorrhage in Japan . Hypertens Res 2009 ; 32 : 759 – 764 . E-II
Koga M, Toyoda K, Yamagami H, Okuda S, Okada Y, Kimura K, Shiokawa Y, Nakagawara J, Furui E, Hasegawa Y, Kario K, Osaki M, Miyagi T, Endo K, Nagatsuka K, Minematsu K . Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators . Systolic blood pressure lowering to 160 mmHg or less using nicardipine in a cute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study) . J Hypertens 2012 ; 30 : 2357 – 2364 . V
Sakamoto Y, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, Shiokawa Y, Nakagawara J, Furui E, Hasegawa Y, Kario K, Arihiro S, Sato S, Kobayashi J, Tanaka E, Nagatsuka K, Minematsu K, Toyoda K . SAMURAI Study Investigators . Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute int racerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study . Stroke 2013 ; 44 : 1846 – 1851 . E-II
Connolly Jr ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P . American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology . Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association . Stroke 2012 ; 43 : 1711 – 1737 . GL
Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW . PRoFESS Study Group . Telmisartan to prevent recurrent stroke and cardiovascular events . New Engl J Med 2008 ; 359 : 1225 – 1237 . II
Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM . PROFESS Investigators . Level of systolic blood pressure within the normal range and risk of recurrent stroke . JAMA 2011 ; 306 : 2137 – 2144 . III
Irie K, Yamaguchi T, Minematsu K, Omae T . The J-curve phenomenon in stroke recurrence . Stroke 1993 ; 24 : 1844 – 1849 . V
The Dutch TIA Trial Study Group . Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke . Stroke 1993 ; 24 : 543 – 548 . II
PATS Collaborating Group . Post-stroke antihypertensive treatment study. A preliminary result . Chin Med J (Engl) 1995 ; 108 : 710 – 717 . II
Eriksson S, Olofsson B, Wester P . Atenolol in secondary prevention after stroke . Cerebrovasc Dis 1995 ; 5 : 21 – 25 . II
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients . New Engl J Med 2000 ; 342 : 145 – 153 . II
Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC . MOSES Study Group . Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES) . Stroke 2005 ; 36 : 1218 – 1226 . II
Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM . SPS3 Study Group . Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial . Lancet 2013 ; 382 : 507 – 515 . II
Rashid P, Leonardi-Bee J, Bath P . Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review . Stroke 2003 ; 34 : 2741 – 2748 . I
Arima H, Chalmers J . PROGRESS: Prevention of Recurrent Stroke . J Clin Hypertens(Greenwich) 2011 ; 13 : 693 – 702 . VI
Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M . Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators . Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis . Circulation 2007 ; 115 : 2969 – 2975 . III
Yamauchi H, Higashi T, Kagawa S, Kishibe Y, Takahashi M . Impaired perfusion modifies the relationship between blood pressure and stroke risk in major cerebral artery disease . J Neurol Neurosurg Psychiatry 2013 ; 84 : 1226 – 1232 . V
Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D . American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research . Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association . Stroke 2011 ; 42 : 227 – 276 . GL
Ebihara S, Suzuki N . Cerebral circulation/metabolism in patients with cerebral circulatory disorder . In: Goto Y, Gotoh F, Tazaki Y, Hasegawa T (eds), Cerebrovascular disease (in Japanese), Life Science Co, Ltd: Tokyo, 1980, pp 116 – 125 . VI
Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M . Blood pressure control and recurrence of hypertensive brain hemorrhage . Stroke 1998 ; 29 : 1806 – 1809 . V
Committee to Prepare New Guidelines for ‘Brain Dock’ . Guidelines for Brain Dock in 2003 (in Japanese). The Japan Brain Dock Society, 2003 . http://www.snh.or.jp/jsbd/pdf/guideline2003.pdf . Accessed 13 June 2008. GL
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM . Silent brain infarcts and the risk of dementia and cognitive decline . New Engl J Med 2003 ; 348 : 1215 – 1222 . IVa
Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J . Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI . Stroke 2000 ; 31 : 1646 – 1650 . V
Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y . Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis . Stroke 2002 ; 33 : 1536 – 1540 . IVb
Leary MC, Saver JL . Annual incidence of first silent stroke in the United States: a preliminary estimate . Cerebrovasc Dis 2003 ; 16 : 280 – 285 . IVb
Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J . PROGRESS CT Substudy Investigators . Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan . Hypertens Res 2004 ; 27 : 147 – 156 . III
Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kimura J . Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients . Stroke 1998 ; 29 : 570 – 576 . IVa
Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE . The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study . Am J Med 1995 ; 98 : 476 – 484 . E-1b
Stewart S, Hart CL, Hole DJ, McMurray JJ . A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study . Am J Med 2002 ; 113 : 359 – 364 . E-1b
Kannel WB, Wolf PA, Benjamin EJ, Levy D . Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates . Am J Cardiol 1998 ; 82 : 2N – 9N . VI
Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM . Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women . Circulation 2009 ; 119 : 2146 – 2152 . E-1b
Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B . Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension . JAMA 2006 ; 296 : 1242 – 1248 . E-Ib
Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC . RACE Investigators . Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study . Eur Heart J 2007 ; 28 : 741 – 751 . III
Lip GY, Frison L, Grind M . SPORTIF Invetigators . Effect of hypertension on anticoagulated patients with atrial fibrillation . Eur Heart J 2007 ; 28 : 752 – 759 . E-Ib
Staessen JA, Wang JG, Thijs L . Cardiovascular protection and blood pressure reduction: a meta-analysis . Lancet 2001 ; 358 : 1305 – 1315 . I
Moser M, Hebert P, Hennekens CH . An overview of the meta-analyses of the hypertension treatment trials . Arch Intern Med 1991 ; 151 : 1277 – 1279 . VI
Fox KM . EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) . Lancet 2003 ; 362 : 782 – 788 . II
Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W . PREVENT Investigators . Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events . Circulation 2000 ; 102 : 1503 – 1510 . II
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ . CAMELOT Investigators . Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial . JAMA 2004 ; 292 : 2217 – 2225 . II
Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K . Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease . Am Heart J 2003 ; 146 : E20 . II
Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C . Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group . Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial . Hypertens Res 2004 ; 27 : 181 – 191 . II
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E . Cholesterol and Recurrent Events Trial investigators . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . New Engl J Med 1996 ; 335 : 1001 – 1009 . II
Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA . World Heart Federation and the Preventive Cardiovascular Nurses Association . AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation . Circulation 2011 ; 124 : 2458 – 2473 . GL
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D . ESC Committee for Practice Guidelines . ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) . Eur Heart J 2011 ; 32 : 2999 – 3054 . GL
Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD . Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction . Hypertension 2008 ; 51 : 48 – 54 . E-Ib
Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC . Treating to New Targets Steering Committee and Investigators . J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial . Eur Heart J 2010 ; 31 : 2897 – 2908 . III
Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP . PROVE IT-TIMI 22 Trial Investigators 2010; 122: 2142–2151. III
Kai H, Ueno T, Kimura T, Adachi H, Furukawa Y, Kita T, Imaizumi T . CREDO-Kyoto Investigators . Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients . J Hypertens 2011 ; 29 : 1889 – 1896 . IVa
Bangalore S, Kumar S, Volodarskiy A, Messerli FH . Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials . Heart 2013 ; 99 : 601 – 613 . I
Ginsburg R, Lamb IH, Schroeder JS, Hu M, Harrison DC . Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm . Am Heart J 1982 ; 103 : 44 – 49 . II
Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, Vanov SK . Amlodipine Study 160 Group . Randomized placebo-controlled trial of amlodipine in vasospastic angina . J Am Coll Cardiol 1993 ; 21 : 1365 – 1370 . II
Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, Urata H, Shimokawa H, Minatoguchi S . Prognostic effects of calcium channel blockers in patients with vasospastic angina—a meta-analysis . Circ J 2010 ; 74 : 1943 – 1950 . IVa
van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, Lie KI . Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates . Int J Cardiol 1995 ; 47 : 217 – 223 . II
Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA . Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina . JAMA 1999 ; 281 : 1927 – 1936 . I
Boberg J, Larsen FF, Pehrsson SK . Visacor Study Group . The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris . Clin Cardiol 1992 ; 15 : 591 – 595 . II
Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH . How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis . J Hypertens 2006 ; 24 : 2131 – 2141 . I
Bangalore S, Messerli FH, Kostis JB, Pepine CJ . Cardiovascular protection using beta-blockers: a critical review of the evidence . J Am Coll Cardiol 2007 ; 50 : 563 – 572 . VI
Pedersen TR . Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction . New Engl J Med 1985 ; 313 : 1055 – 1058 . II
Dargie HJ . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial . Lancet 2001 ; 357 : 1385 – 1390 . II
The Multicenter Diltiazem Postinfarction Trial Research Group . The effect of diltiazem on mortality and reinfarction after myocardial infarction . New Engl J Med 1988 ; 319 : 385 – 392 . II
Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators . Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects . Am J Cardiol 2004 ; 93 : 969 – 973 . II
Yui Y, Shinoda E, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C . Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group . Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy) . J Hypertens 2007 ; 25 : 2019 – 2026 . III
Nakagomi A, Kodani E, Takano H, Uchida T, Sato N, Ibuki C, Kusama Y, Seino Y, Munakata K, Mizuno K, Takano T . Secondary preventive effects of a calcium antagonist for ischemic heart attack: randomized parallel comparison with β-blockers . Circ J 2011 ; 75 : 1696 – 1705 . II
Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, Yamamoto T, Oyaizu M, Kimura A, Yamamoto K, Yabushita H, Katori R . Secondary Prevention Group . Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction . Circulation 1997 ; 95 : 2368 – 2373 . III
Pfeffer MA, Braunwald E, Moy LA, Basta L, Brown Jr EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM . The SAVE Investigators . Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial . New Engl J Med 1992 ; 327 : 669 – 677 . II
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM . Valsartan in Acute Myocardial Infarction Trial Investigators . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both . New Engl J Med 2003 ; 349 : 1893 – 1906 . II
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure . Lancet 1993 ; 342 : 821 – 828 . II
Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC . Trandolapril Cardiac Evaluation (TRACE) Study Group . A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction . New Engl J Med 1995 ; 333 : 1670 – 1676 . II
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M . Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction . New Engl J Med 2003 ; 348 : 1309 – 1321 . II
Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A . JCARE-GENERAL Investigators . Characteristics and outcomes of patients with heart failure in general practices and hospitals . Circ J 2007 ; 71 : 449 – 454 . E-1b
Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mm Hg . JAMA 1970 ; 213 : 1143 – 1152 . II
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J . Randomized Aldactone Evaluation Study Investigators . The effect of spironolactone on morbidity and mortality in patients with severe heart failure . New Engl J Med 1999 ; 341 : 709 – 717 . II
The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure . New Engl J Med 1991 ; 325 : 293 – 302 . II
The SOLVD Investigattors . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions . New Engl J Med 1992 ; 327 : 685 – 691 . II
Cohn JN, Tognoni G . Valsartan Heart Failure Trial Investigators . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . New Engl J Med 2001 ; 345 : 1667 – 1675 . II
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S . CHARM Investigators and Committees . Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme . Lancet 2003 ; 362 : 759 – 766 . II
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K . CHARM Investigators and Committees . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial . Lancet 2003 ; 362 : 772 – 776 . II
Dickstein K, Kjekshus J . OPTIMAAL Steering Committee of the OPTIMAAL Study Group . Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan . Lancet 2002 ; 360 : 752 – 760 . II
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH . U.S. Carvedilol Heart Failure Study Group . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure . New Engl J Med 1996 ; 334 : 1349 – 1355 . II
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, VÃtovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P . MERIT-HF Study Group . Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) . JAMA 2000 ; 283 : 1295 – 1302 . II
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial . Lancet 1999 ; 353 : 9 – 13 . II
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL . Effect of carvedilol on survival in severe chronic heart failure . New Engl J Med 2001 ; 344 : 1651 – 1658 . II
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith Jr SC . American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), International Society for Heart and Lung Transplantation, Heart Failure Society of America . ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Ca rdiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantatio n; Endorsed by the Heart Failure Society of America . Circulation 2001 ; 104 : 2996 – 3007 . GL
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW . 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation . Circulation 2009 ; 119 : 1977 – 2016 . GL
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A . ESC Committee for Practice Guidelines . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European So ciety of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC . Eur Heart J 2012 ; 33 : 1787 – 1847 . GL
Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL . Prospective Randomized Amlodipine Survival Evaluation Study Group . Effect of amlodipine on morbidity and mortality in severe chronic heart failure . New Engl J Med 1996 ; 335 : 1107 – 1114 . II
Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G . Blood pressure reduction and renin–angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis . Eur Heart J 2009 ; 30 : 679 – 688 . I
Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D . Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute . Circulation 2009 ; 119 : 3070 – 3077 . IVb
Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B . Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators . Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction . Hypertension 2010 ; 55 : 241 – 248 . II
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J . CHARM Investigators and Committees . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial . Lancet 2003 ; 362 : 777 – 781 . II
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J . PEP-CHF Investigators . The perindopril in elderly people with chronic heart failure (PEP-CHF) study . Eur Heart J 2006 ; 27 : 2338 – 2345 . II
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A . I-PRESERVE Investigators . Irbesartan in patients with heart failure and preserved ejection fraction . New Engl J Med 2008 ; 359 : 2456 – 2467 . II
Lund LH, Benson L, Dahlström U, Edner M . Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction . JAMA 2012 ; 308 : 2108 – 2117 . E-1b
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP . Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study . New Engl J Med 1990 ; 322 : 1561 – 1566 . E-1b
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C . Prognostic significance of serial changes in left ventricular mass in essential hypertension . Circulation 1998 ; 97 : 48 – 54 . E-1b
Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K . Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study . Circulation 2007 ; 116 : 700 – 705 . E-Ib
Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, Oba K, Takeda K, Higaki J, Nakao K . CASE-J trial Group . Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial . Hypertens Res 2009 ; 32 : 248 – 254 . E-Ib
Sato A, Hayashi M, Saruta T . Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension . Hypertens Res 2002 ; 25 : 837 – 842 . II
Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S . Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy . Circ J 2006 ; 70 : 995 – 1000 . II
Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ . The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents . Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents . Circulation 1997 ; 95 : 2007 – 2014 . II
Miller AB, Reichek N, St John Sutton M, Iyengar M, Henderson LS, Tarka EA, Bakris GL . Importance of blood pressure control in left ventricular mass regression . J Am Soc Hypertens 2010 ; 4 : 302 – 310 . II
Iseki K, Tohyama K, Matsumoto T, Nakamura H . High Prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD) . Hypertens Res 2008 ; 31 : 249 – 255 . IVa
Sakaguchi Y, Shoji T, Kawabata H, Niihata K, Suzuki A, Kaneko T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y . High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study . Clin J Am Soc Nephrol 2011 ; 6 : 995 – 1000 . E-II
Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S . Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study . Hypertens Res 2008 ; 31 : 433 – 441 . E-Ib
Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J . National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group . Preserving renal function in adults with hypertension and diabetes: a consensus approach . Am J Kidney Dis 2000 ; 36 : 646 – 661 . GL
Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y . An overview of regular dialysis treatment in Japan (as of 31 December 2010) . Ther Apher Dial 2012 ; 16 : 483 – 521 . E-II
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J . Blood pressure and end-stage renal disease in men . New Engl J Med 1996 ; 334 : 13 – 18 . E-Ib
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW . American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention . Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Ca rdiology, and Epidemiology and Prevention . Circulation 2003 ; 108 : 2154 – 2169 . GL
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy . Lancet 1997 ; 349 : 1857 – 1863 . II
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM . Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL . Kidney Int 2004 ; 65 : 2309 – 2320 . IVa
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R . RENAAL Study Investigators . The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study . Kidney Int 2003 ; 63 : 1499 – 1507 . IVa
Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, Saitoh S, Sakata K, Okayama A, Ueshima H . NIPPON DATA90 Research Group . Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90 . Circ J 2006 ; 70 : 954 – 959 . IVa
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH . Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization . Arch Intern Med 2004 ; 164 : 659 – 663 . E-Ib
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization . New Engl J Med 2004 ; 351 : 1296 – 12305 . E-Ib
Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T, Miura K, Okamura T, Ueshima H . EPOCH-JAPAN Research Group . Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan . Am J Epidemiol 2013 ; 178 : 1 – 11 . E-Ia
National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification . Am J Kidney Dis 2002 ; 39 : S1 – 266 . GL
Japanese Society of Nephrology . Evidence-based Clinical Practice Guideline for CKD 2013 (in Japanese) . Tokyo Igakusha: Tokyo . 2013 . GL
Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT . Chronic Kidney Disease Prognosis Consortium . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis . Lancet 2010 ; 375 : 2073 – 2081 . E-Ia
Stevens PE, Levin A . Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members . Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline . Ann Intern Med 2013 ; 158 : 825 – 830 . GL
Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, Ito S . Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study . Hypertens Res 2011 ; 34 : 1106 – 1110 . E-Ib
Ito S . Cardiorenal syndrome: an evolutionary point of view . Hypertension 2012 ; 60 : 589 – 595 . VI
Umemura T, Kawamura T, Sakakibara T, Mashita S, Hotta N, Sobue G . Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults . Am J Hypertens 2012 ; 25 : 430 – 436 . E-II
Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S . Prevalence of chronic kidney disease in the Japanese general population . Clin Exp Nephrol 2009 ; 13 : 621 – 630 . E-II
Yokoyama H, Kawai K, Kobayashi M . Japan Diabetes Clinical Data Management Study Group . Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10) . Diabetes Care 2007 ; 30 : 989 – 992 . E-II
Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, Kalra PA, O’Donoghue DJ, New JP . The unrecognized prevalence of chronic kidney disease in diabetes . Nephrol Dial Transplant 2006 ; 21 : 88 – 92 . E-II
Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A . Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes . Diabetes 2007 ; 56 : 1727 – 1730 . IVa
Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S . Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy . Hypertens Res 2007 ; 30 : 325 – 334 . II
Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, Navis G, Laverman GD . HOlland NEphrology STudy Group . Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial . BMJ 2011 ; 343 : d4366 . II
Lambers Heerspink HJ, de Borst MH, Bakker SJ, Navis GJ . Improving the efficacy of RAAS blockade in patients with chronic kidney disease . Nat Rev Nephrol 2013 ; 9 : 112 – 121 . VI
Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P . Sodium intake, ACE inhibition, and progression to ESRD . J Am Soc Nephrol 2012 ; 23 : 165 – 173 . E-Ib
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S . Body mass index and the risk of development of end-stage renal disease in a screened cohort . Kidney Int 2004 ; 65 : 1870 – 1876 . E-Ib
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S . Influence of smoking and obesity on the development of proteinuria . Kidney Int 2002 ; 62 : 956 – 962 . E-Ib
Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakker SJ, de Jong PE, Gansevoort RT . Impact of weight change on albuminuria in the general population . Nephrol Dial Transplant 2007 ; 22 : 1619 – 1627 . IVa
Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN . Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts . Nephrol Dial Transplant 2010 ; 25 : 1173 – 1183 . IVa
Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S . Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis . Clin J Am Soc Nephrol 2009 ; 4 : 1565 – 1574 . IVa
Kramer H, Shoham D, McClure LA, Durazo-Arvizu R, Howard G, Judd S, Muntner P, Safford M, Warnock DG, McClellan W . Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study . Am J Kidney Dis 2011 ; 58 : 177 – 185 . IVa
Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, Sarnak MJ . Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD . Am J Kidney Dis 2008 ; 52 : 49 – 57 . IVa
Orth SR . Smoking and the kidney . J Am Soc Nephrol 2002 ; 13 : 1663 – 1672 . VI
Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG . DEMAND investigators . Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective . Kidney Int 2006 ; 69 : 2057 – 2063 . E-II
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH . The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis . Ann Intern Med 1996 ; 124 : 627 – 632 . I
Pan Y, Guo LL, Jin HM . Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials . Am J Clin Nutr 2008 ; 88 : 660 – 666 . I
Robertson L, Waugh N, Robertson A . Protein restriction for diabetic renal disease . Cochrane Database Syst Rev 2007 ; CD002181 : I
Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, Shikata K, Murakami Y, Tomino Y, Yamada K, Araki SI, Kashiwagi A, Kikkawa R . Low-Protein Diet Study Group . Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial . Diabetologia 2009 ; 52 : 2037 – 2045 . II
Japanese Society of Nephrology . Guidelines for Life Style and Dietary Therapy for CKD patients . Jpn J Nephrol 1997 ; 39 : 1 – 37 . Japanese. GL
Smart NA, Williams AD, Levinger I, Selig S, Howden E, Coombes JS, Fassett RG . Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease . J Sci Med Sport 2013 ; 16 : 406 – 411 . GL
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A . European Society of Hypertension . Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document . J Hypertens 2009 ; 27 : 2121 – 2158 . GL
de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S, Chalmers J . ADVANCE Collaborative Group . Lowering blood pressure reduces renal events in type 2 diabetes . J Am Soc Nephrol 2009 ; 20 : 883 – 892 . II
Uzu T, Kida Y, Yamauchi A, Kume S, Isshiki K, Araki S, Koya D, Haneda M, Kashiwagi A, Maegawa H, Kikkawa R . The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria . J Am Soc Hypertens 2012 ; 6 : 124 – 131 . E-Ib
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore Jr J, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ . Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations . J Am Soc Nephrol 2005 ; 16 : 3027 – 3037 . IVa
Kawamori R, Fujita T, Matsuoka H, Umemura S, Saito Y . Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study . Diabetes Res Clin Pract 2009 ; 83 : 241 – 248 . IVb
Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG . African American Study of Kidney Disease and Hypertension Study Group . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial . JAMA 2002 ; 288 : 2421 – 2431 . II
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G . Modification of Diet in Renal Disease Study Group . The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease . New Engl J Med 1994 ; 330 : 877 – 884 . II
Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G . REIN-2 Study Group . Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial . Lancet 2005 ; 365 : 939 – 946 . II
Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M . KEEP Investigators . Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP) . Arch Intern Med 2012 ; 172 : 41 – 47 . IVa
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL . Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study . Ann Intern Med 1995 ; 123 : 754 – 762 . II
Appel LJ, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X . AASK Collaborative Research Group . Intensive blood-pressure control in hypertensive chronic kidney disease . New Engl J Med 2010 ; 363 : 918 – 929 . IVa
Upadhyay A, Earley A, Haynes SM, Uhlig K . Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier . Ann Intern Med 2011 ; 154 : 541 – 548 . IVa
Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS . The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study . Ann Intern Med 2005 ; 142 : 342 – 351 . II
Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V . Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis . CMAJ 2013 ; 185 : 949 – 957 . I
Weiner DE, Tighiouart H, Levey AS, Elsayed E, Griffith JL, Salem DN, Sarnak MJ . Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease . J Am Soc Nephrol 2007 ; 18 : 960 – 966 . E-Ib
Ninomiya T, Perkovic V, Gallagher M, Jardine M, Cass A, Arima H, Anderson C, Neal B, Woodward M, Omae T, MacMahon S, Chalmers J . PROGRESS Collaborative Group . Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial . Kidney Int 2008 ; 73 : 963 – 970 . III
Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig JC, Huxley R . Proteinuria and stroke: a meta-analysis of cohort studies . Am J Kidney Dis 2009 ; 53 : 417 – 425 . E-Ia
Sarafidis PA, Khosla N, Bakris GL . Antihypertensive therapy in the presence of proteinuria . Am J Kidney Dis 2007 ; 49 : 12 – 26 . VI
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS . AIPRD Study Group . Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis . Ann Intern Med 2003 ; 139 : 244 – 252 . E-Ia
Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K . CASE-J Study Group . Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study . Hypertens Res 2009 ; 32 : 505 – 512 . III
Keane WF, Eknoyan G . Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation . Am J Kidney Dis 1999 ; 33 : 1004 – 1010 . GL
Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K . An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone . Kidney Int 2013 ; 83 : 167 – 176 . III
Baba S . J-MIND Study Group . Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics . Diabetes Res Clin Pract 2001 ; 54 : 191 – 201 . II
Hayashi K, Kumagai H, Saruta T . Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment . Am J Hypertens 2003 ; 16 : 116 – 122 . II
Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T . Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria . Kidney Int 2006 ; 70 : 151 – 156 . II
Ogawa S, Mori T, Nako K, Ito S . Combination therapy with renin– angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy . Hypertens Res 2008 ; 31 : 1147 – 1155 . II
Sato A, Hayashi K, Naruse M, Saruta T . Effectiveness of aldosterone blockade in patients with diabetic nephropathy . Hypertension 2003 ; 41 : 64 – 68 . V
Bianchi S, Bigazzi R, Campese VM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease . Kidney Int 2006 ; 70 : 2116 – 2123 . II
Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P . ’U’curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. . Kidney Int 1998 ; 54 : 561 – 569 . IVa
Mazzuchi N, Carbonell E, Fernández-Cean J . Importance of blood pressure control in hemodialysis patient survival . Kidney Int 2000 ; 58 : 2147 – 2154 . IVa
Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, Sunagawa H, Yoshihara K, Yoshi S, Toma S, Kowatari T, Wake T, Oura T, Fukiyama K . Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients . Kidney Int 1997 ; 51 : 1212 – 1217 . IVa
Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG, Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK . Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study . Kidney Int 2012 ; 82 : 570 – 580 . E-II
Iseki K, Nakai S, Shinzato T, Morita O, Shinoda T, Kikuchi K, Wada A, Kimata N, Akiba T . Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan . Ther Apher Dial 2007 ; 11 : 183 – 188 . E-II
Shoji T, Tsubakihara Y, Fujii M, Imai E . Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients . Kidney Int 2004 ; 66 : 1212 – 1220 . IVa
Agarwal R, Alborzi P, Satyan S, Light RP . Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial . Hypertension 2009 ; 53 : 500 – 507 . II
Moriya H, Ohtake T, Kobayashi S . Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAB) in patients on haemodialysis . Nephrol Dial Transplant 2007 ; 22 : 1198 – 1204 . V
The Japanese Society for Dialysis Therapy . Clinical Guidelines for the Evaluation and the Treatment of Cardiovascular Complications in Hemodialysis Patients . J Jpn Soc Dia Ther 2011 ; 44 : 358 – 362 . Japanese. GL
The Japanese Circulation Society . Guidelines for Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection (JCS 2011) . The Japanese Circulation Society. Japanese. GL
Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M . Chronic ß-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection . Eur J Cardiothorac Surg 2001 ; 19 : 606 – 610 . IVa
Leach SD, Toole AL, Stern H, DeNatale RW, Tilson MD . Effect of β-adrenergic blockade on the growth rate of abdominal aortic aneurysms . Arch Surg 1988 ; 123 : 606 – 609 . IVb
Hackam DG, Thiruchelvam D, Redelmeier DA . Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study . Lancet 2006 ; 368 : 659 – 665 . IVb
Isselbacher ME . Disease of the Aorta . In: Douglas P, Libby P Bonow RO (eds), Braunwald’ Heart Disease, a text book of cardiovascular medicine . 7th edn. Philadelphia, 2005, 1428. VI
Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, Thompson SG, Walker NM . Multicentre Aneurysm Screening Study Group . The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial . Lancet 2002 ; 360 : 1531 – 1539 . II
Shores J, Berger KR, Murphy EA, Pyeritz RE . Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome . New Engl J Med 1994 ; 330 : 1335 – 1341 . II
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd . Angiotensin II blockade and aortic-root dilation in Marfan's syndrome . New Engl J Med 2008 ; 358 : 2787 – 2795 . V
MacSweeney ST, Ellis M, Worrell PC, Greenhalgh RM, Powell JT . Smoking and growth rate of small abdominal aortic aneurysms . Lancet 1994 ; 344 : 651 – 652 . IVa
Brewster DC, Cronenwett JL, Hallett Jr JW, Johnston KW, Krupski WC, Matsumura JS . Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery . Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery . J Vasc Surg 2003 ; 37 : 1106 – 1117 . GL
Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT . Exercise training for claudication . New Engl J Med 2002 ; 347 : 1941 – 1951 . VI
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG . II TASC Working Group . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) . J Vasc Surg 2007 ; 45 : (Suppl S) S5 – S67 . GL
Radack K, Deck C . adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials . Arch Intern Med 1991 ; 151 : 1769 – 1776 . I
Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, Gori T, Munzel T . Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial . Hypertension 2011 ; 58 : 148 – 154 . II
Rights and permissions
About this article
Cite this article
Chapter 6. Hypertension associated with organ damage. Hypertens Res 37, 301–314 (2014). https://doi.org/10.1038/hr.2014.9
Published:
Issue Date:
DOI: https://doi.org/10.1038/hr.2014.9